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Abstract: Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) have been shown to alleviate 
pain and inflammation, regulate motility and appetite, and produce anti-cancer, anxiolytic, and 
neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2), or via peroxisome 
proliferator-activated receptor α (PPAR-α) stimulation. FAEs and ECs are synthesized by a series of 
endogenous enzymes, including N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD), 
diacylglycerol lipase (DAGL), or phospholipase C (PLC), and their metabolism is mediated by several 
metabolic enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), N-
acylethanolamine acid amidase (NAAA), or cyclooxygenase-2 (COX-2). Over the last decades, 
increasing the concentration of FAEs and ECs through the inhibition of degrading enzymes has been 
considered to be a viable therapeutic approach to enhance their anti-nociceptive and anti-inflammatory 
effects, as well as protecting the nervous system. 
Introduction 
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Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) are biosynthetic ligands, which are 
widely distributed in the central nervous system (CNS), the immune system, and the peripheral tissues of 
mammals (e.g. human, monkey, dog, mouse and rat).1 
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are two of the most studied members of the 
endocannabinoid family. Indeed, there is a basal amount of ECs in tissues. The balance and circulation of 
ECs in different tissues are regulated by related synthases, degrading enzymes, and transporters. The rapid 
accumulation of ECs is observed in tissues during injury.1-3 AEA was identified as an agonist of CB1 
receptors by Devane in 1992.4 Furthermore, 2-AG was demonstrated to be another biosynthetic agonist 
of CB1 receptors in 1995.5 Although AEA levels are much lower than 2-AG levels in the brain, AEA has 
been determined to show greater in vitro affinity for CB1 receptors (Ki = 50-100 nM) than 2-AG (Ki = 1-
10 μM) in a number of binding assays.6 Nevertheless, AEA showed only partial agonist effects, whereas 
2-AG exerted full efficacy in a [35S]GTPγS assay. Additionally, 2-AG has been repored to bind to CB2, 
another cannabinoid receptor subtype. Although AEA was also identified as a CB2 ligand, it exerts lower 
affinity for CB2 than CB1.6 Aside from CB1 and CB2 receptors, AEA and 2-AG also serve as ligands for 
non-cannabinoid targets, including the transient receptor potential cation channel subfamily V member 1 
(TRPV1).1 
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) belong to a large family of FAEs, a 
class of lipid mediators which consist of saturated FAEs, monounsaturated FAEs, and polyunsaturated 
FAEs. The formation of FAEs is tissue-dependent during the course of pro-inflammatory stimuli or tissue 
damage. For instance, inflammation suppresses the production of PEA and OEA in macrophages, whereas 
the elevation of AEA levels is detected in the same cells.1 In addition, the formation of PEA and OEA 
appears to be less stimulus-dependent in comparison with AEA in dorsal root ganglion neurons and skin 
cells.1,7 PEA was identified as a peroxisome proliferator-activated receptor α (PPAR-α) agonist by Lo 
Verme and co-workers in 2004.8 OEA was described as a PPAR-α agonist in 2003.9 To date, there is 
sufficient evidence to demonstrate that PEA and OEA do not bind CB receptors with significant affinity. 
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Biosynthesis of FAEs and ECs  
FAEs are derived from a membrane precursor, termed N-acylphosphatidylethanolamine (NAPE), 
which is formed from phosphatidylcholine and phosphatidylethanolamine by N-acyltransacylase (NAT). 
On the one hand, NAPE is transformed into FAEs and phosphatidic acid by NAPE-phospholipase D 
(NAPE-PLD) directly.10-12 On the other hand, NAPE is hydrolyzed by phospholipase C (PLC) to generate 
phospho-FAE (P-FAE), which is further dephosphorylated to yield FAEs by phosphatase (e.g. protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) in lymphoid cells).11-13 Alternatively, NAPE can 
also be deacylated by α/β-hydrolase 4 (ABHD4) to generate lyso-NAPE, which is followed by lyso-PLD-
mediated removal of acylphosphatidyl moiety to give FAEs directly, or ABHD4-mediated deacylation to 
yield glycerophospho-FAE (GP-FAE). Afterwards, GP-FAE is catabolized into FAEs by a metal-
dependent phosphodiesterase GDE1 (Figure 1).11,12 
Conversely, 2-AG is obtained from a membrane phospholipid, termed phosphatidylinositol-4,5-
bisphosphate (PIP2). PIP2 is hydrolyzed by the β-isoform PLC (PLC-β) to yield 1,2-diacylglycerol (DAG), 
which is further degraded into 2-AG through the action of diacylglycerol lipase (DAGL), initiated by 
calcium signaling.10 Additionally, 2-AG can be also synthesized from phosphatidyl-inositol (PI) via 
phospholipase A1 (PLA1) and lyso-PLC. First, PI is degraded by PLA1 to produce a lysophospholipid, 
and then lyso-PLC converts this lysophospholipid into 2-AG (Figure 2).10 
Biodegradation of FAEs and ECs 
Fatty acid amide hydrolase (FAAH) was first identified as an enzyme which hydrolyzes AEA into 
arachidonic acid (AA) and ethanolamine.14 Additionally, AEA and AA can be oxidized by 
cyclooxygenase-2 (COX-2) to generate proalgesic prostamides, such as prostaglandin H2 ethanolamide 
(PGH2-EA) and prostaglandin H2 (PGH2), respectively.1 There is growing evidence that cytochrome P450 
participates in the catabolism of AEA.15 Although FAAH is confirmed as the primary hydrolytic enzyme 
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for hydrolysis of AEA, N-acylethanolamine acid amidase (NAAA) has been identified as another 
hydrolase for AEA (Figure 1).16 
Monoacylglycerol lipase (MAGL) has been demonstrated to be the major hydrolase responsible for 
the transformation of 2-AG into AA and glycerol. COX-2-regulated oxidations also convert 2-AG into 
proalgesic lipids, such as prostaglandin H2 glycerol (PGH2-G).1,15 Apart from MAGL and FAAH, the 
degradation of 2-AG is attributed to α/β-hydrolase 6 and 12 (ABHD6 and 12).17 In addition, 2-AG levels 
can be affected by FAAH in vitro but not in intact cells.17,18 Particularly, MAGL is responsible for 
approximately 85% of 2-AG hydrolysis in mouse brain, while ABHD6 and ABHD12 were shown to 
mediate around 9% and 4% of 2-AG degradation, respectively. Less than 2% of 2-AG metabolism is 
attributed to other ezymes (Figure 2).17 
PEA and OEA are both substrates of FAAH and NAAA. Particularly, FAAH principally metabolizes 
PEA and OEA into palmitic acid and oleic acid, respectively, in neurons, while NAAA plays a crucial 
role in downregulating PEA levels in macrophages (Figure 1).1 Furthermore, fatty acid amide hydrolase-
2 (FAAH-2), an isozyme of FAAHidentified only in primates, not in rodents, exhibits superior capacity 
to hydrolyze OEA compared to PEA or AEA.19 
FAEs and ECs-mediated effects  
The damage of nerves or tissues results in the activation of macrophages by stimulation of toll-like 
receptor-4 (TLR4), the activation of mast cells, and the entry of calcium ions into neurons.1,20 Next, pro-
inflammatory cytokines (such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)) are 
produced by macrophages and mast cells. The release of neurotransmitters such as acetylcholine (ACh) 
is initiated by Ca2+
 
in neurons.20 Additionally, activation of TLR4 is also accompanied by the production 
of AEA and platelet-activating factor (PAF) by macrophages. PAF further activates PAF receptors, which 
induces the formation and release of 2-AG. The synthesis of AEA and 2-AG by neurons is Ca2+ and/or 
neuroreceptor-dependent.1,21,22 Newly formed AEA and 2-AG bind to CB1/CB2 receptors on macrophages 
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and mast cells and to the CB1 receptor on neurons. Activation of these CB receptors is followed by the 
inhibition of pro-inflammatory cytokines produced by macrophages and mast cells, the production of anti-
inflammatory cytokines (such as IL-4 and IL-10) by macrophages, the suppression of calcium signaling, 
and the inhibition of neurotransmitter release in neurons, thereby blocking action potential and excitation 
transmission (Figure 3a).1,20 
Alternatively, TNF-α and IL-1β released from macrophages and mast cells decrease PEA levels 
through the modulation of NAPE-PLD-dependent FAEs synthesis8 and activate the nuclear factor kappa 
B (NF-κB).23 Then, NF-κB further upregulates the expression of COX-2 and pro-inflammatory cytokine 
(e.g. TNF-α, IL-1, IL-6, and IL-8).23,24 PEA-mediated anti-inflammation is mainly caused by the 
activation of PPAR-α, associated with negative activation of NF-κB, and thereby inhibition of pro-
inflammatory cytokines formation and COX-2 expression (Figure 3b).23,24 
Although PEA and OEA are not endogenous ligands for cannabinoid receptors CB1 and CB2, it is 
argued that they enhance AEA-dependent activities through purported “entourage” effects.25 In 1998, 
Calignano and colleagues discovered an interesting phenomenon that the PEA-mediated anti-nociceptive 
effect was suppressed by a CB2 receptor antagonist 1 (SR144528, Figure 4) in an in vivo assay after a 0.1 
mg/kg intravenous injection in mice.26 Indeed, AEA and PEA have been identified as two effective 
substrates for FAAH.14,27 As a competitive substrate for FAAH, PEA has been shown to attenuate the 
biodegradation of AEA. OEA has also been demonstrated to modulate the concentrations of AEA in a 
similar mechanism.28 
FAAH 
FAAH was identified and cloned by Cravatt and co-workers in 1996.27 It is an integral membrane-
bound enzyme, belonging to the serine hydrolase family.10 Its first X-ray crystal structure was disclosed 
in 2002.29 Its binding site comprises three functional channels: the membrane access channel (MAC), the 
acyl-chain binding pocket (ABP), and the cytosolic port (CP), which are relevant to transporting the 
 6
substrate to the catalytic site, providing the accommodation of the acyl chain during catalysis, and 
removing the leaving group after hydrolysis, respectively.30 Notably, the substrate is surrounded by the 
catalytic triad Ser241-Ser217-Lys14231 and the oxyanion hole residues (including Ser241, Gly240, 
Gly239, and Ile238)30 during catalysis (Figure 5). Firstly, Lys142 deprotonates Ser217, which then 
deprotonates Ser241. The activated hydroxyl group of Ser241 further interacts with the electrophilic 
carbonyl group of the substrate, which is accompanied by the formation of an acylated enzyme adduct 
and the release of ethanolamine.31 At the end of the hydrolysis, the acyl group of the substrate is released 
from the acyl-enzyme complex through the action of a water molecule (Figure 6).30,31 The oxyanion hole 
has been demonstrated to stabilize the intermediate during the catalytic triad-mediated catalysis.32 
Recently, the residues Phe432 and Trp531 were identified to form a “gate” in the MAC. The rotation of 
Phe432 was demonstrated to result in an “open” or “closed” state of the MAC, which is accompanied by 
a size alteration of the MAC and the ABP (Figure 7).33 The “open” state is proposed to favor the access 
of substrate into binding cavities. Afterwards, the “closed” state provides enlarged ABP, which allows 
the easy access of substrate from the MAC into the ABP.34 The shift of the conformational equilibrium in 
favor of “open” or “closed” state is due to the hydrophobic interaction between Phe432 and substrate. 
Molecular dynamics simulations identified that unsaturated substrates (i.e. AEA and OEA) rather than 
saturated substrates (i.e. PEA) are more likely to trigger the rotation of Phe432, which might be attributed 
to the fact that the hydrophobic interaction with C=C is stronger than the interaction with C–C. This 
finding explains why unsaturated substrates are preferred for FAAH rather than saturated substrates (i.e. 
hydrolysis rates: AEA (4 C=C) > OEA (1 C=C) > PEA (0 C=C)).34 Hence, inhibitors, which are designed 
based on this “gate”, might be more selective over other serine hydrolases with a different “gate” 
composition. As another two important amino acid residues in the MAC, Asp403 and Arg486 might 
facilitate the access of substrate into binding cavities (Figure 5).33 
FAAH is first responsible for the degradation of several FAEs (such as AEA, PEA and OEA). Thus, 
FAAH inhibitors can alter signaling of FAEs and thereby induce numerous biological responses (such as 
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pain relief, anti-inflammation, injury repair, and neuroprotection) by stimulation of CB1/CB2 receptors 
and/or PPAR-α.1,8,21,22. 
NAAA 
NAAA, an amidohydrolase of the N-terminal cysteine hydrolase family, was isolated from rat lung 
in 200135 and cloned from rat lung in 2005.36 NAAA is highly expressed in macrophages and peripheral 
tissues.37 NAAA-mediated hydrolysis is initiated by self-proteolysis (from 48 kDa form to 30 kDa active 
form) at pH ~4.5 in the extracellular medium.38 Despite the absence of a crystal structure, Cys131 and 
Cys126 were identified as catalytic residues of NAAA in rat and human, respectively.7,39 Exemplified by 
human NAAA, its catalytic site comprises three principal residues Cys126, Arg142 and Asp145.37 In 
particular, as the reactive nucleophilic moiety of NAAA, the thiol group of Cys126 interacts with the 
electrophilic carbonyl group of the substrate to generate an acyl-enzyme adduct.39,40 Mutation of any one 
of these three residues leads to a total loss of catalytic activity, which means that Cys126, Arg142 and 
Asp145 play a crucial role in the interaction with the substrate.41 Unlike FAAH, which exerts optimal 
activity over a wide pH range from 8.5 to 10, NAAA is more pH-sensitive. NAAA is almost inactive at 
neutral, alkaline, or strong acidic pH and its catalytic activity occurs only at pH 4.5-5.37,39,41 
Recently, NAAA inhibitors have been regarded as a novel, potentially-effective treatment for 
inflammation, pain, and immune disorders, since they enhance PPAR-α-mediated anti-inflammatory, 
anti-nociceptive and immunomodulatory capacities through the increase of related FAEs levels.8,22 
MAGL 
MAGL, a membrane-associated hydrolase, is another important member of serine hydrolase family. 
It was purified from rat adipose tissue and cloned from mouse adipocytes by Karlsson in 1997.42 The first 
X-ray crystal structures of MAGL were independently reported by Bertrand et al and by Lambert and co-
workers in 2009.43,44 Ser122-Asp239-His269 has been identified as the catalytic triad of MAGL.42 
Especially, the nucleophilic hydroxyl group of Ser122 was identified to interact with the electrophilic 
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carbonyl group of the substrate.44,45 The residues Leu174 and Leu176 form the entrance to the catalytic 
site, whereas Phe93 and Phe209 display “gate”-like functions (Figure 8).34,43 Interestingly, three cysteines 
(Cys201, Cys208, Cys242), which are close to the catalytic triad, were hypothesized to stabilize MAGL 
conformation and additionally interact with some substrates (such as maleimides).44,46,47 These cysteines 
were once considered as beneficial targets for the development of selective MAGL inhibitors over other 
serine hydrolases.45 The functional site of MAGL comprises the ABP, the alcohol-binding channel and 
the glycerol exit channel, which serve to accommodate the acyl chain, the glycerol moiety, and the leaving 
group, respectively (Figure 8).43 Especially, mild alkaline pH (pH 8.0) is preferred for MAGL-mediated 
hydrolysis.45 Unsaturated monoacylglycerols (MAGs) are preferred substrates for MAGL in comparison 
with diacylglycerols (DAGs), triacylglycerols (TAGs) and saturated MAGs.45,48 Moreover, MAGL exerts 
a tissue-dependent control of monoglyceride metabolism. MAGL inhibition brings about an increase of 
2-AG levels in the brain, whereas the dramatic elevation of other MAGs (such as mono-oleoylglycerol) 
after MAGL blockade mostly occurs in peripheral tissues.48  
Since MAGL was reported to be responsible for the degradation of 2-AG, inhibition of MAGL has 
been viewed as a new approach to produce analgesic, anti-inflammatory, and neuroprotective effects. 
1,17,18
 
Accordingly, over several decades, enhancing the levels of ECs and FAEs via the inhibition of 
relevant endogenous metabolic enzymes has been considered as an interesting approach to suppress 
inflammation, pain, and other disorders. In this context, several pathways to terminate the catabolism of 
endogenous lipids will be reviewed.  
Enzyme inhibitors 
According to their interactive mechanisms, enzyme inhibitors can be classified as reversible, 
slowly/partially reversible and irreversible inhibitors.49 As illustrated in Figure 9, the inhibitor initially 
interacts with the enzyme to form a transition state complex EI. Afterwards, the EI either reverses to 
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release free enzyme E or undergoes a tightening interaction (e.g. covalent binding and/or conformational 
change of enzyme). Irreversible inhibitors induce a permanent tightening form EI* (Kd = 0), whereas 
slowly/partially reversible inhibitors undergo a conversion from tightening form EI* to transition state 
form EI (Kd > 0).49,50 The EI complex can be reversed by a rapid dilution for reversible inhibitors, whereas 
reversal of a slowly/partially reversible inhibitor-enzyme complex EI* requires specific treatments (e.g. 
dialysis).49 
FAAH inhibitors 
The first-generation FAAH inhibitors were designed with reactive groups able to form a covalent 
bond with the catalytic residue Ser241.51 For example, the widely known serine hydrolase inhibitor, 
phenylmethylsulfonylfluoride 2 (PMSF) (Figure 10) was demonstrated to completely block FAAH-
mediated activities and increase concentrations of AEA in vitro.14 Moreover, fluorophosphonate 
derivatives 3 (MAFP)52 and trifluoromethyl ketones 4 and 553 (Figure 10) were disclosed to inhibit FAAH. 
The replacement of a trifluoromethyl group by a methyl group brought about a dramatic decrease of 
FAAH inhibitory potency. This result revealed that the electrophilicity of the carbonyl group exerted a 
notable effect on the molecule’s binding to FAAH.54 Although these first generation inhibitors were 
capable of blocking FAAH in in vitro pharmacological assays, their lack of selectivity made them poor 
candidates for preclinical applications. Nevertheless, the disclosure of these inhibitors inspired the further 
exploration of selective FAAH inhibitors. 
Over the last decades, the development of FAAH inhibitors has significantly progressed and a 
plethora of selective FAAH inhibitors have been designed and synthesized. Hereafter, recent FAAH 
inhibitors will be reviewed. 
1. α-Ketoheterocycle derivatives 
The first α-ketoheterocycles developed as selective FAAH inhibitors were reported by Boger and 
co-workers in 2000.55,56 Their work represented a significant breakthrough in the development of selective 
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FAAH inhibitors. The α-ketoheterocycles were derived from the trifluoromethyl oleyl ketone 5 (Figure 
10). Different heterocycles were introduced to replace the trifluoromethyl group.54 Researchers argued 
that oxazolopyridines give rise to enhanced potency against FAAH in comparison with other heterocycles 
(such as benzoxazoles, compound 6, Ki = 370 nM) (Figure 11). Of note, oxazolo[4,5-b]pyridine (7) and 
oxazolo[5,4-c]pyridine (8) afforded the most obvious improvement in FAAH inhibition (Ki = 2.3 and 3.7 
nM, respectively). Oxazolo[4,5-c]pyridine (9) and oxazolo[5,4-b]pyridine (10) gave rise to an 
approximately 7 to 11-fold increase in potency (Ki = 7.2 and 11 nM, respectively) in comparison with 5.55 
It was shown that oxazolopyridines enhanced the electrophilicity and reactivity of carbonyl groups of α-
ketoheterocycle derivatives. Additionally, the heterocyclic nitrogen of the pyridine ring contributes to the 
improvement of FAAH inhibitory efficacy, which is probably due to its property to form an H-bond with 
Thr236. Indeed, an X-ray co-crystal structure (PDB: 3PPM) of non-covalently bound state of α-
ketoheterocycle-FAAH complex identified that an H-bond was established between the pyridine ring and 
Thr236,57 which was proposed to lock the inhibitor and favor the formation of tetrahedral intermediate 
with Ser241. Furthermore, different alkyl and phenylalkyl groups were introduced instead of the oleyl 
moiety. Structure-activity relationships illustrated that alkyl α-ketoheterocycles with 7 to 11 carbons 
displayed the best FAAH inhibition (0.57 ≤ Ki ≤ 0.75 nM, Figure 11). Particularly, the introduction of a 
phenyl ring at the end of the acyl chain gave rise to a significant enhancement of FAAH inhibition of the 
molecules (0.20 ≤ Ki ≤ 0.52 nM, Figure 11).55 Moreover, optimization of the alkyl chain linker between 
the oxazolopyridine and the phenyl ring was carried out, indicating an optimal chain length of 5 carbons 
(11, Ki = 0.20 nM, Figure 11).54,55  
An extensive development of α-ketoheterocycle derivatives was continued by Boger and co-workers. 
In 2004, compound 12 (OL-135, Ki = 4.7 nM, Figure 11) was reported to be the best studied FAAH 
inhibitor.58 It was discovered following structural modifications on α-keto heterocycle-based derivatives. 
The preliminary pharmacological data showed that the introduction of 5-substituted oxazoles on the 
ketone provided a significant improvement in FAAH inhibition by the molecules.58 Specifically, 
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pyrimidinyl (13, Ki = 16 nM), pyridazinyl (14, Ki = 14 nM), pyridinyl (15, Ki = 18 nM), oxazolyl (16, Ki 
= 12 nM), and thiazolyl (17, Ki = 16 nM) substituents at the C5 position of an oxazole ring lead to potent 
FAAH inhibitors (Figure 11). At the same time, research on phenylalkyl-substituted α-keto oxazole 
derivatives was undertaken. It was disclosed that compounds with 5 to 8 carbons between the phenyl and 
the oxazole ring exhibited good inhibitory potency for FAAH, and a C6 chain was determined to be the 
optimal chain length (Figure 11).59 These 5-phenylalkyl(pyridin-2-yl)oxazole derivatives displayed potent 
selectivity for FAAH over triacylglycerol hydrolase (TGH) and the membrane-associated hydrolase 
KIAA1363.58,60 According to these results, compound 12 was identified as a potential candidate for 
preclinical development with potent inhibition and selectivity for FAAH.58 Moreover, compound 12 was 
demonstrated to elevate AEA levels in the brain and spinal cord and induced CB1-dependent analgesia in 
vivo,61 and was unable to activate cannabinoid receptors (CB1 and CB2) directly or affect P450-dependent 
activities in vivo.54 A co-crystal structure of 12-FAAH revealed that the phenylalkyl group of 12 was 
located in the ABP, while its carbonyl function interacted with Ser241 to form a tetrahedral adduct (Figure 
12a).33 
Furthermore, structure-activity relationships on 12 were undertaken. The pyridinyl group at the C5 
position of the oxazole ring was replaced by different non-aromatic or aromatic substituents. The 
pharmacological assay data revealed that removal of the nitrogen atom of the pyridine led to an 
appreciable loss of inhibition (Figure 12b).62 Structure-activity relationships indicated non-aromatic 
substituents (such as cyano, trifluoromethyl, and methyl carboxylate groups) with electron-withdrawing 
properties were found to enhance the inhibitory potency of the molecules (Figure 12b).62 Boger and co-
workers found a fundamental relationship between the Ki values and the Hammett σp constant of non-
aromatic substituents. They made a good correction plot of -Log Ki (µM) versus σp (Figure 12c)62, which 
could be useful for the design of α-ketoheterocycles-based FAAH inhibitors and the prediction of Ki 
values. Overall, most derivatives with a 2-pyridinyl substituent at the C5 position of the oxazole ring 
exhibited the favorable selectivity for FAAH over other serine enzymes (e.g. TGH, KIAA1363).62 
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Modifications of the acyl moiety of 12 were performed. The terminal phenyl ring of the acyl group 
was replaced by a series of aromatic groups. Almost all compounds possessed effective potency except 
for 2-pyridinyl (18, Ki = 120 nM) and carboxyphenyl (19, 20 and 21, Ki > 600 nM) derivatives that 
manifested a dramatic loss of activity (Figure 12b).63 In addition, a phenyl ring substituted with electron-
withdrawing groups (such as chloro or trifluoromethyl) enhanced FAAH inhibition in comparison with 
12 (Figure 12b).63 It was noteworthy that the 2,3-dichlorophenyl derivative 22 (Ki = 0.9 nM, Figure 12b) 
exerted approximately a 5-fold better affinity for FAAH than 12.63 The biphenyl-4-ethyl chain derivative 
23 (Ki = 0.75 nM, Figure 12d) provided around a 6-fold stronger affinity for FAAH, as compared to 
12.63,64 The five-membered ring of 12 was also modified by introducing additional heteroatoms. 1,2,4-
Oxadiazoles 24 and 25 (Ki = 0.34 nM and 1.1 nM, respectively, Figure 12d) and 1,3,4-oxadiazole 26 (Ki 
= 0.29 nM, Figure 12d) showed dramatically enhanced inhibition with respect to 12.65 
A systematic exploration of phenylhexyl-α-keto oxazole derivatives has been carried out over the 
last few years. Several molecules displayed potent FAAH inhibitory capacity. Typically, a compound 
with a phenoxyphenylhexyl side chain (27, CE-12, Ki = 4.4 nM, Figure 12d) elevated AEA levels in brain 
with duration of action more than 10 h.66 It was determined to significantly relieve pain in a chronic 
constriction injury (CCI) model post a 50 mg/kg oral dose. 
Recently, a new series of extended α-keto oxazole derivatives were reported to target a new binding 
site: the Cys269 of the CP of FAAH.67 These compounds were obtained by introducing different groups 
at the C5 position of the pyridine ring of 12. Derivatives with electrophilic groups (such as compound 28, 
Figure 13a) were shown to increase FAE levels in mouse brain. Activity-based protein profiling (ABPP) 
assays showed that these newly developed molecules possessed high selectivity for FAAH over other 
serine hydrolases, including TGH, KIAA1363, MAGL, and ABHD6. In addition to interacting with 
Ser241, these new α-keto oxazole-based FAAH inhibitors were determined to bind covalently and 
irreversibly to the Cys269 by dialysis and X-ray crystal structure studies (Figures 13b and 13c).67,68 
Additional binding to Cys269 was argued to endow these novel inhibitors with improved selectivity and 
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prolonged inhibitory activity. Compared to the reversible FAAH inhibitor 12, these irreversible inhibitors 
had a greater ability to enhance AEA signaling over longer periods in mice.67 
2. Carbamates 
The first class of aryl carbamate derivatives as FAAH inhibitors was disclosed in 2003.69 Compound 
30 (URB597, IC50 = 4.6 nM, Figure 14) was shown to inhibit FAAH in the nanomolar range and elevate 
brain AEA levels after a 0.3 mg/kg intraperitoneal injection in rats.69,70 Compound 30 was devoid of 
activity in a panel of receptors (e.g. CB1/CB2, NOP1 receptor), ion channels (e.g. Na+, K+, and Ca2+ 
channels), transporters (e.g. AEA transporter), and enzymes (e.g. COX1/2 and MAGL) at 10 μM.71 
Nevertheless, compound 30 was shown to inactivate carboxylesterases and block the expression of 
tyrosine hydroxylase as off-target effects.72,73 It manifested potent anxiolytic properties without affecting 
appetite or body temperature in models of elevated zero-maze and the isolation-induced ultrasonic 
emission in rats (0.1-0.3 mg/kg intraperitoneal injection) and produced pain relief in the complete 
Freund’s adjuvant (CFA) model of arthritis pain in rats (0.5 mg/kg intraperitoneal injection).69,71 The X-
ray crystal structure of a 30-FAAH adduct illustrated that the rotatable N-cyclohexyl ring occupied the 
ABP. Adjacent to the cyclohexyl group, the carbamate group was confirmed to form a covalent bond with 
Ser241 (Figures 15a and 15b).74 The biphenyl moiety, which serves as a leaving group, was located in the 
CP. 
Although compound 30 had excellent selectivity for FAAH in brain without affecting other serine 
hydrolases, it was found to interfere with the function of several liver carboxylesterases.72 To reinforce 
the selectivity for FAAH and reduce carboxylesterase off-target effects, a further extension was 
performed, based on the scaffold of 30. As a representative second generation aryl carbamate-based 
FAAH inhibitor, compound 31 (URB694, IC50 = 30 nM, Figure 14), which was obtained by the 
modification of the substituents of the biphenyl moiety, had weakened affinity for carboxylesterases in 
comparison with 30.75 The introduction of polar and electron-donating groups lowered the electrophilicity 
of the carbamate group , which reduced its hydrogen bond donor interactions, but resulted in improved 
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selectivity for FAAH.75 As a result of focusing on the attributes of 30 and 31, a novel carbamate derivative 
32 (URB937, IC50 = 26.8 nM, Figure 14), containing both carbamoyl and hydroxyl substituents on the 
biphenyl moiety, was designed. Compound 32 is a selective FAAH inhibitor over MAGL in vitro, which 
produces inhibitory effect in peripheral tissues (e.g. liver) rather than CNS (e.g. brain).76 It attenuated 
inflammation-related and neural injury-induced pain in mice after a 1 mg/kg intraperitoneal dose through 
CB1-dependent activity.76 
In addition to the O-aryl carbamates, other series of carbamate derivatives, such as oxime77 and enol78 
carbamates, have been developed over the last decades. Particularly, compound 33 (ST4070, IC50 = 9 nM, 
Figure 14) was disclosed as a reversible inhibitor in dialysis studies and a highly selective FAAH inhibitor 
versus other targets in the endocannabinoid system, including CB1, CB2, TRPV1, NAPE-PLD, MAGL, 
and DAGL.78 Due to a lack of an X-ray co-crystal structure of a FAAH-33 adduct, the reversible 
mechanism remains unclear. Generally speaking, given its structural similarity with 30, the biphenyl enol 
moiety of 33 is expected to act as a leaving group, which is accompanied by the covalent carbamoylation 
of Ser241.78 As illustrated in Figure 16, the groups forming covalent bonds with Ser241 differ between 
30 and 33, and are N-cyclohexylformamide (secondary amide) and piperidine-1-formyl (tertiary amide), 
respectively. The co-crystal structure of FAAH-30, showed that the polar hydrogen of N-
cyclohexylformamide forms an H-bond with Ser193, which stabilizes the carbamonyl-FAAH adduct. 
Conversely, due to the lack of a suitable hydrogen, piperidine-1-formyl of 33 is not expected to establish 
an H-bond connection with the enzyme. The lack of such an H-bond renders the FAAH-33 adduct unstable 
and hydrolyzable, which confers reversibility to 33. In addition, the latter was able to elevate brain AEA 
and PEA levels in mice at a 30 mg/kg oral dose and was capable of alleviating neuropathic pain and anti-
anxiety at 30 mg/kg oral doses in models of streptozotocin-induced diabetes and CCI-induced pain in 
mice.78,79 As a reversible FAAH inhibitor, compound 33 can be regarded as a lead for the development of 
a clinical candidate. 
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Recently, the replacement of phenyl group in 30 by a triazolylmethyl group or the introduction of a 
pyrazole moiety between the two phenyl groups was performed.80,81 Since a triazolylmethoxy group acts 
as a poorer leaving group than phenoxy, such a replacement was deemed to confer higher stability to the 
molecules. This hypothesis was confirmed by pharmacokinetics studies. O-Substituted triazolylmethyl 
carbamates (such as 34 and 35, Figure 17) were detected in rat plasma 7 hours after administration, 
whereas O-substituted 4-biphenyl carbamate 29 (URB524, IC50 = 25.6 nM, Figure 14) was undetectable 
at the same time.80 Hence, several O-substituted triazolylmethyl carbamates were prepared by Colombano 
and co-workers. Particularly, N- and O-disubstituted 1,2,3-triazolylmethyl carbamates (such as 36, IC50 = 
5.8 nM, Figure 17) exerted optimal inhibitory potency. The replacement of 1,2,3-triazolylmethyl (35, IC50 
= 26.2 nM, Figure 17) with 1,2,4-triazolylmethyl (37, IC50 = 51500 nM, Figure 17) resulted in a dramatic 
decrease of potency against FAAH, which might be due to the altered electrophilic reactivity of the 
carbamate.80 This research on metabolic stability of the molecules in plasma can be considered as an 
encouraging starting point for prolonging the duration of action. Moreover, a series of O-pyrazolylphenyl 
carbamates bearing a 3-alkyloxycarbonyl group on the pyrazole moiety also exerted potent capacity to 
inhibit FAAH and high selectivity over MAGL (compounds 38, 39, 40, 41, and 42, 11 nM ≤ IC50 ≤ 29 
nM, selectivity index (SI) > 1000, Figure 18).81 The newly introduced alkyloxycarbonyl function at the 
3-position of the pyrazole ring was expected to form an H-bond with the hydroxyl group of Thr488, since 
this latter interaction was previously identified as a means to improve reactivity and selectivity of the 
molecules toward FAAH.70,81 These compounds were determined to reversibly bind to FAAH by dialysis 
studies. This observation is meaningful for the further development of novel selective and reversible 
FAAH inhibitors.81 
Most recently, Lehr and co-workers disclosed a novel series of ω-imidazolyl and ω-tetrazolyl alkyl 
carbamates as potent FAAH inhibitors.82 Although compound 43 (IC50 = 5.3 nM, Figure 19) manifested 
optimal potency against FAAH at single-digit nanomolar concentrations, its instability in plasma made it 
a poor candidate for systemic administration. Compounds 44 and 45 (IC50 = 11 and 81 nM, respectively, 
 16
Figure 19) exerted potent FAAH inhibition in the two-digit nanomolar range. However, they were shown 
to be degraded by carboxylesterases in porcine plasma.82 Specifically, compounds 46 and 47 (IC50 = 110 
and 200 nM, respectively, Figure 19) possessed moderate FAAH inhibitory activities, but suitable stability 
in the presence of liver fractions, plasma or albumin.82 Further investigation of structure-activity 
relationships indicated that a C6 to C8 alkyl chain, notably a C7, appended to the tetrazolyl ring was 
favorable for FAAH inhibitory potency.82 
3. Sulfonylfluorides 
The first covalent but nonselective sulfonylfluoride FAAH inhibitor disclosed was compound 2.14 
To improve selectivity over other serine enzymes, an extension of the acyl chain was carried out.83 
Sulfonylfluorides bearing a C14, C16, or C18 length chains exhibited weak affinity for CB1 receptor and 
blocked the hydrolysis of AEA.83 For instance, the representative alkylsulfonylfluoride 48 (AM374, IC50 
= 13 nM, Figure 20a) with a C16 length side chain, manifested approximately 20-fold more potency than 
compound 2 (IC50 = 290 nM).83 Nevertheless, compound 48 was previously disclosed to affect outer-
membrane phospholipase A-dependent activities.84 To improve selectivity for FAAH over other serine 
enzymes, a further modification of the acyl chain was performed. The carbon chain between the phenyl 
ring and the sulfonylfluoride group of compound 2 was extended from C1 to C8 length. Particularly, 
phenylalkyl sulfonylfluorides with five to seven carbons exhibited potent inhibitory potency and 
selectivity for FAAH.85 The introduction of a hydroxyl or benzyloxy group at the 4-position of the phenyl 
ring appeared to enhance the inhibitory potency for FAAH.85 Specifically, 4-hydroxyphenylpentyl 
sulfonylfluoride 49 (AM3506, IC50 = 48 nM, Figure 20a) exerted a potent inhibitory effect for FAAH, 
without triggering other serine hydrolase-mediated degradation at a dose of 0.1 mg/kg in mouse brain and 
liver. Nevertheless, it inhibited MAGL and ABHD6 as off-targets at a dose of 1 mg/kg.86 Moreover, 
compound 49 was disclosed to have a favorable property in suppressing blood pressure, and depressing 
heart rate in a hypertensive model by stimulating CB1 receptor. In addition, the administration of 49 was 
identified to be devoid of hyperglycemia effects.86 The absence of inhibitory activities for several serine 
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hydrolases in liver at a dose of 1 mg/kg made 49 a favorable lead compound, since the inhibition of hepatic 
FAAH could result in the elevation of hepatic AEA signaling associated with diet-dependent fatty 
liver.87,88 A molecular docking study illustrated that the two oxygen atoms of the sulfonyl group formed 
H-bonds with Ser241 and the oxyanion hole of FAAH, respectively, the phenylalkyl side chain occupied 
the ABP and the phenol interacted with Thr488 (Figure 20b).85 In particular, the additional formation of 
a hydrogen bond between the hydroxyl group of 49 and the Thr488 of FAAH was expected to be 
advantageous for the improvement of selectivity and inhibitory activity.70,85  
4. Ureas 
The first generation urea-based FAAH inhibitors were a result of serendipity. Indeed, compound 50 
(LY-2183240, Figure 21), which belongs to the earliest urea-based FAAH inhibitors, was previously 
developed to upregulate AEA levels by preventing AEA from transporting across the plasma 
membrane.2,3 In 2006, compound 50 was found to strongly inhibit FAAH and other brain serine 
hydrolases.89 Its carbamoyl moiety was shown to covalently and irreversibly interact with Ser241 of 
FAAH as shown using mass spectrometry and dilution analysis.89 Switching AEA regulation from 
transporter inhibition to FAAH inhibition is a favorable starting point for the development of urea-based 
FAAH inhibitors. During the last decade, several major series of urea-based FAAH inhibitors have been 
explored by Johnson & Johnson, Pfizer and Takeda.  
In 2006, Johnson & Johnson described a series of piperazinyl and piperidinyl ureas as FAAH 
inhibitors.90 Typically, compound 51 (JNJ-1661010, Figure 21) exerted potent inhibitory efficacy for both 
rat FAAH and human FAAH (IC50 = 34 and 33 nM, respectively).91 Compound 51 was discovered to be 
a FAAH inhibitor by high-throughput screening (HTS) of Johnson & Johnson’s chemical library.91 
Afterwards, an exploration of N-substitutions and an introduction of different functions on the phenyl ring 
appended to the 1,2,4-thiadiazole ring was performed. Structure-activity relationships illustrated (Figure 
22): (1) The introduction of a fluoro or chloro group at the 2-position of the N-phenyl ring provides an 
obvious improvement of inhibitory activity for rat FAAH, and a moderate increase of inhibitory capacity 
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for human FAAH, compared to 51. (2) The introduction of different substituents on the phenyl ring 
appended to the 1,2,4-thiadiazole ring leads to a dramatic loss of potency against FAAH. (3) The 
replacement of the N-phenyl ring with heteroaryl groups (such as 3-/4-pyridinyl, 4-pyrimidinyl, 6-
methoxypyrimidine-4-yl or benzo[c][1,2,5]thiadiazole-4-yl groups) result in a remarkably enhanced 
inhibitory potency for both rat and human FAAH with respect to 51.91 Dialysis and mass spectrometry 
studies identified that the phenyl-1,2,4-thiadiazol-5-piperazinyl moiety of compound 51 covalently and 
reversibly bound to FAAH, while the aniline moiety acted as a leaving group during hydrolysis (Figure 
23).91 Compound 50, but not compound 51 inactivated liver esterase.91 The absence of inhibitory effects 
toward liver esterases makes 51 a potential attractive lead compound.  
Replacement of the phenylthiadiazole and the N-phenyl moieties of 51 with arylmethyl and aromatic 
groups, respectively, was carried out in 2012. Overall, compound 52 (JNJ-40355003, Figure 21) 
manifested optimal capacity to elevate three related FAEs (AEA, PEA, OEA) levels in rat, dog, and 
cynomolgus monkey plasma via the inhibition of FAAH (IC50 (hFAAH) = 1.4 nM, IC50 (rFAAH) = 33 
nM in a irreversible manner (dialysis studies).92 It was noteworthy that 52 did not affect FAAH-2 (IC50 > 
10 μM), whereas another two potent FAAH inhibitors 12 and 30 were shown to inactivate FAAH-2 at 
nanomolar concentrations (IC50 = 13.4 and 5 nM, respectively).19 Compound 52 dramatically increased 
FAE levels in monkey plasma after a 5 mg/kg oral administration.19,92 
Recently, Janssen Research, part of Johnson & Johnson, disclosed a series of spirocyclic diamine 
core-based urea FAAH inhibitors, which were obtained through the modification of the aromatic amine 
and piperazine moieties of 52.93 Compounds 53, 54, and 55 (Figure 24) exhibited remarkable FAAH 
inhibition activities (IC50  (hFAAH) = 27, 80 and 125 nM, respectively).93 A further screening of different 
aromatic amine functions was performed. The pharmacological assays indicated that 56 (JNJ-42119779, 
Figure 24), acted as an irreversible inhibitor in dialysis studies, displaying optimal inhibitory efficacy 
against both rat and human FAAH (IC50 (hFAAH) = 8 nM, IC50 (rFAAH) = 9 nM) and produced analgesia 
in a spinal nerve ligation (SNL) model after a 20 mg/kg oral dose. Replacement of a 2,7-
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diazaspiro[3.5]nonane group with a 2,6-diazaspiro[3.3]heptane group (57, IC50 (hFAAH) = 18 nM, IC50 
(rFAAH) = 42 nM, Figure 24) resulted in a slight loss of inhibitory potency against FAAH, but almost 
complete loss of ability to raise central FAEs (AEA, OEA and PEA) levels in vivo.93 More recently, 
compound 58 (JNJ-42165279, Figure 24), a selective and slowly reversible (dialysis assays) piperazine 
urea-based FAAH inhibitor developed by Johnson & Johnson, was reported to be in phase II clinical 
trials.94 Compound 58 has been reported to time-dependently inhibit rat and human FAAH (IC50 (hFAAH) 
= 70 nM, IC50 (rFAAH) = 313 nM) and to elevate brain FAEs (AEA, PEA, and OEA) levels until 24 h 
post-dose in rats. Moreover, it exhibited high selectivity versus a panel of enzymes, transporters, 
receptors, and ion-channels at 10 μM.94 Compound 58 was demonstrated to produce analgesia in a rat 
SNL model (22 mg/kg oral dose).94 
Pfizer discovered a series of piperidine/piperazine-based urea-FAAH inhibitors through a HTS 
screening campaign. Of note, compounds 59 (PF-622, Figure 21) and 60 (PF-750, Figure 21) were 
reported to dramatically inhibit FAAH (IC50 (hFAAH) = 33 and 12.5 nM, respectively).50 Furthermore, a 
time-dependent inhibitory activity assay was performed.50 Human FAAH was preincubated with 
inhibitors and the substrate was added after a certain time. IC50 values for 59 and 60 were dramatically 
decreased from 0.991 µM to 0.033 µM and 0.595 µM to 0.0162 µM respectively after a longer 
preincubation time (60 min instead of 5 min). Compound 30 also exerted similar time-dependent 
properties (IC50 = 0.986 µM after 5 min, IC50 = 0.109 µM after 60 min). Conversely, the prolonged 
preincubation time did not affect the FAAH inhibitory capacity of 12.50 Time-dependent properties of 
irreversible FAAH inhibitors are probably due to their ability to form a covalent substrate-FAAH complex 
or induce a conformational change in the enzyme. Hence, the inhibitory activities of irreversible FAAH 
inhibitors were assessed with kinact/Ki values (kinact: maximal rate of enzyme deactivation at a saturating 
concentration of inhibitor) instead of IC50 values by Pfizer.50 The higher the value, the better the activity. 
kinact/Ki values were determined for the irreversible FAAH inhibitors 30 and 60. Although these two FAAH 
inhibitors were reported with remarkable IC50 values, they only showed modest kinact/Ki values (kinact/Ki = 
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1,590 M-1s-1 1 and 791 M-1s-for 30 and 60, respectively).95 This observation indicated that 30 and 60 might 
possess only moderate binding affinity for FAAH or inactivate FAAH at a moderate rate. 
Compounds 59 and 60 displayed no detectable activity for other serine enzymes at a 500 μM 
concentration in vitro, and at a dose of 30 mg/kg in vivo in ABPP assays. However, compounds 30 and 
12 had off-target serine enzyme interactions under the same experimental conditions.50 The co-crystal 
structure of 60-FAAH indicated: the urea functions of 60 covalently reacted with Ser241 of FAAH, the 
piperidine moiety was positioned in the ABP of FAAH (Figure 25), and the aniline group attached to the 
CP serving as the leaving group after hydrolysis.50,96 Compounds 59 and 60 were shown to irreversibly 
bind to FAAH, since the hydrolysis capacity of FAAH did not recover after a rapid dilution.50 
Inspired by the structures of 59 and 60, a series of benzothiophene-based piperazine/piperidine ureas 
were described as FAAH inhibitors. The replacement of the N-phenyl ring of benzothiophene urea 
derivatives with the N-pyridine-3-yl group led to enhanced inhibition by the molecules (Figure 26).97 
Moreover, the introduction of additional substituents on the pyridine ring was reported to markedly alter 
the inhibitory potency against FAAH. In particular, structure-activity relationships showed that a 
substituent at the 6-position led to the dramatic loss of inhibition potency, except for a methoxy group 
(Figure 26). For instance, a diethylamino substituent at the 6-position of the pyridine ring resulted in 
around a 20-fold loss of inhibitory activity for human FAAH, in comparison with the amino substituent. 
It seems that steric effects limit the interaction of the molecule with FAAH.97 Furthermore, substituent 
optimization on the benzothiophene was carried out (Figure 26). The methyl group at the 3-position of 
the benzothiophene seemed to be essential for the FAAH inhibitory capacity of the molecule. Indeed, the 
replacement of this methyl group with an ethyl group was shown to slightly decrease the inhibitory 
efficacy and the remove of this substituent dramatically reduce the inhibitory activity (kinact/Ki = 2401 M-
1s-1, 1402 M-1s-1 and 695 M-1s-1, respectively). The introduction of small groups at the 4-/5-positions 
appeared to have a slight impact on inhibitory efficacy. However, the introduction of an ethoxy group at 
the 6-position of the benzothiophene brought about a complete loss of inhibitory activity (kinact/Ki = 14 M-
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1s-1).97 The binding model revealed that the 6-ethoxy benzothiophene substituent was too large to be 
suitably placed in the binding channel of FAAH according to the mutual exclusion between the ethoxy 
group and Met436.97 Most of these developed benzothiophene urea derivatives were determined to be 
highly selective as shown using competitive ABPP. Compound 61 (PF-465, Figure 26) alleviated pain 
response in the complete Freund’s adjuvant (CFA) model of inflammatory pain in rats after a 10 mg/kg 
dose, with efficacy comparable to that of the nonsteroidal anti-inflammatory drug (NSAID) naproxen at 
the same dose.97 
As previously described, compound 60 only showed moderate affinity for FAAH. To improve the 
binding affinity for FAAH, replacement of the quinoline with different biaryl ether functions was 
performed and the pharmacological activities were profiled as kinact/Ki values.95 These modifications led 
to the discovery of a potent, selective, covalent, irreversible FAAH inhibitor, compound 62 (PF-3845, 
Figure 27).95 The profile of inhibitory potency indicated that 62 possessed an impressive kinact/Ki value of 
12600 M-1s-1 for hFAAH, which was 8 times and 16 times more than 30 and 60, respectively. Indeed, 
compound 62 showed rapid elevation of brain AEA, PEA, and OEA levels in mice brain. The significant 
increase of brain AEA levels was still detected 24 hours post a 10 mg/kg intraperitoneal administration. 
Conversely, the action of 30 in improving brain AEA levels was not observable 7 hours post a 10 mg/kg 
intraperitoneal dose.95 Compound 62 produced CB1-/CB2-dependent pain relief in various models (such 
as mechanical allodynia model and CFA-induced inflammatory pain) at a 10 mg/kg oral dose.95 
Selectivity profiling by competitive ABPP showed that 62 exhibited high selectivity for FAAH without 
affecting other serine enzymes. Apart from the high selectivity, compound 62 also exerted prolonged 
duration of enzyme inactivation (> 24 h) and high oral bioavailability (> 80%).95 These advantageous 
characteristics make 62 a useful tool for the further exploration and investigation of endocannabinoid 
system-mediated multiple biological responses.95 Recently, compound 62 was demonstrated to promote 
neuronal survival and alleviate brain damage in a traumatic brain injury (TBI) model in mice post a 5 
mg/kg intraperitoneal dose.98 
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Further determination of the X-ray crystal structure of a 62-FAAH complex showed that the 
carboxamide moiety of 62 covalently interacted with the hydroxyl group of Ser241, the 3-aminopyridine 
group was positioned in the CP and acted as a leaving group during catalysis, and the biaryl ether 
piperidine moiety was bound to the ABP.95 Notably, the conformation of FAAH was variable according 
to the rotation of Phe432 and Met436. The data reported showed that the inhibitors induced 
conformational changes.77,95 As exemplified by 62, overlay of X-ray co-crystal structures of 62-FAAH 
and 60-FAAH indicated that the trifluoromethyl group induced a conformational shift of Phe432 from the 
ABP to the MAC. (Figures 28a and 28b) This conformational switching is accompanied by a rotation of 
Met436, and results in the expansion of the ABP and the easier access of inhibitors or substrates from 
MAC into the ABP.95 In fact, the replacement of the trifluoromethyl group of 62 with smaller substituents 
(such as methyl, fluoro) resulted in a sudden decrease of inhibitory potency, because the van der Waals 
interactions between the small substitutions and Phe432/Met436 was too weak to alter the conformation 
of the enzyme.95 Additionally, switching a trifluoromethyl group from the 5-position of pyridine ring to 
the 3/6-position also impaired inhibitory capacity, which was possibly due to the steric clash between the 
inhibitor molecular and the enzyme.95 
To improve the inhibitory efficacy, a C=C linker was introduced into the basic scaffold of 62.99 In 
particular, the introduction of a C=C linker between the piperidine ring and the aromatic group confers 
several advantageous properties. For instance, the C=C moiety provides a rigid conformation with fewer 
rotatable bonds, lower conformational energy, and improves the likelihood of interactions with the ABP 
(e.g. Phe432).99 Indeed, pharmacological assay results indicated that piperidine derivatives with the C=C 
linker (63, kinact/Ki (hFAAH) = 21600 M-1s-1) exerted enhanced inhibitory potency in comparison with 62. 
Additionally, the replacement of N-pyridin-3-yl by pyrazin-2-yl (64) or pyridazine-3-yl (65) dramatically 
improved the inhibitory efficacy (Figure 27), and also decreased the hydrophobicity of the molecular and 
alter physicochemical parameters (such as clog P).99 Subsequently, compound 65 (PF-04457845, Figure 
27), a novel potent, highly selective, covalent, and irreversible FAAH inhibitor was identified as a clinical 
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candidate. Compound 65 was shown by competitive ABPP to possess high selectivity over numerous 
serine enzymes in kidney, spleen, and testis at 100 μM and exhibit no off-target activity against a panel 
of receptors, ion channels, and transporters.99,100 It possessed remarkable pharmacokinetic properties in 
dogs and humans, including rapid absorption after oral administration, a low clearance rate, a high 
bioavailability of 88% and 58% in rats and dogs, respectively, a low probability of drug-drug interaction 
based on in vitro cytochromes P450 (CYPs) inhibition investigations, and a long duration of action lasting 
until 24 hours post-dose.99 Compound 65 was found to elevate FAEs (e.g. AEA and OEA) levels and 
alleviate inflammation-related pain in a CFA model of inflammatory pain in rats (0.1 mg/kg oral dose) 
through CB1/CB2-dependent activities without affecting motility or body temperature.99,100 Although oral 
administration of 0.5-40 mg 65 also brought about the elevation of plasma FAEs levels, it failed to produce 
analgesia in patients with pain induced by osteoarthritic knee in clinical trials.101 The complete loss of 
analgesic potency in humans might be attributed to the difference in biological responses after FAAH 
inhibition between humans and rodents. Two hypotheses were suggested for this clinical trial failure by 
Pfizer. Firstly, complex human emotions related to pain are not observable in rodent models.102 Indeed, 
human pain observation was demonstrated to be significantly influenced by emotionality. Pain sensation 
can be attributed to heightened anxiety or depression. Secondly, there is sufficient evidence that CB 
receptor activation induced by AEA elevation after FAAH inhibition is equivalent to that induced by 
exogenous CB receptor agonists in rodents. However, this has not been confirmed in humans.101 Overall, 
pain and its related symptoms are complicated and might differ in various species. How to translate pain 
symptoms into rational and reliable data needs be considered carefully. Moreover, pain can be induced 
by multiple conditions (e.g. inflammation, cancer, or injury), therefore, analgesic mechanisms might 
differ depending on the types of pain. Nevertheless, clinical trials of compound 65 in other disorders (e.g. 
post-traumatic stress disorders and Tourette syndrome) are ongoing. 
 [11C-carbonyl] 65 (Figure 27) was shown to be a suitable candidate for FAAH positron emission 
tomography (PET), which can be used for the neuroimaging study of FAAH and the clinical research.103 
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Furthermore, optimization of the core between the urea function and the aromatic group of 65 was 
performed. The pharmacological assay identified two series of novel potent urea-based FAAH inhibitors 
bearing a 1-oxa-8-azaspiro[4.5]decane or a 7-azaspiro[3.5]nonane core instead of a piperidine.104 Three 
compounds (66, 67, and 68, Figure 29) from these two series were profiled and assessed for their 
selectivity versus more than 200 human serine hydrolases. The competitive ABPP assay indicated that 
these three compounds were devoid of off-targets at 100 μM. They were further determined to exert low 
clearance and a low risk of drug-drug interactions.104 To further improve potency against FAAH and 
optimize CNS-dependent drug properties, the exploration and screening of aromatic moieties led to the 
identification of a 7-azaspiro[3.5]nonane urea 69 (PF-04862853, kinact/Ki value = 4190 and 5820 M-1s-1 
towards human and rat FAAH, respectively, Figure 29) as one of the optimal FAAH inhibitors to date.105 
In addition, compound 69 was determined to possess suitable physiochemical (clogP = 3.8) and 
pharmacokinetic properties (a half-life of 7.1 h and 53% bioavailability in rats, a half-life of 7.8 h and 
33% bioavailability in dogs), display a pronounced anti-inflammatory effect at 0.3 mg/kg, almost totally 
inhibit FAAH in brain at 0.3 mg/kg, and substantially increase AEA levels to reach the maximum 
concentration in brain at 1 mg/kg in a CFA model of inflammatory pain in rats.105 Given its advantageous 
drug-like properties, compound 69 was selected as a lead compound.105 
Recently, Takeda developed a series of heterocyclic piperazine ureas as FAAH inhibitors.106,107 
These novel inhibitors were inspired by two identified FAAH inhibitors 5191 and 70 (Figure 30). It was 
hypothesized that the replacement of the phenyl ring of 51 with benzoisoxazolyl might improve the 
inhibitory potency.106 In this case, 71 (Figure 30) was discovered by the hydridization of 51 and 70. 
Compound 71 was demonstrated to exhibit remarkable inhibitory capacity against human FAAH (IC50 = 
4.8 nM). However, this N-benzoisoxazolyl substituted urea derivative has poor aqueous solubility and 
disappointing bioavailability (5%) in rats.106 Hence, the replacement of benzoisoxazolyl with isoxazole, 
pyridazine, or pyridine was performed to improve aqueous solubility and other physicochemical 
parameters. Particularly, N-(3,4-dimethylisoxazol-5-yl) substituted derivative 72 (Figure 30) exerted 
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enhanced inhibitory efficacy (IC50 = 1.7 nM) and moderate aqueous solubility (1.6 µg/mL) with respect 
to 71.106 Moreover, the replacement of the 1,2,4-thiadiazole group with a thiazole ring seemed to improve 
both inhibitory potency and aqueous solubility (Figure 30, IC50 = 0.92 nM, solubility of 38 µg/mL). 
Additionally, the exploration of substituents on the terminal phenyl ring was carried out. Notably, the 2-
/4-monosubstituted fluoro group and 2,4-disubstituted fluoro group on the terminal phenyl ring appeared 
to be favorable for inhibition and for maintaining modest aqueous solubility (Figure 30).106 It is 
noteworthy that mono- or di-substituted fluoro groups at the 2/4 position of the terminal phenyl group 
enabled potent oral bioavailability (70-98%) in rats and the ability to cross the BBB.106 Compound 73 
(Figure 30) not only possessed the optimal inhibitory activity for human and rat FAAH (IC50 = 0.43 and 
0.46 nM, respectively), but also exerted remarkable analgesic potency in the acetic acid-induced writhing 
model in mice at doses of 10 and 30 mg/kg (oral administration).106  
To improve the aqueous solubility, pyridazine and pyrimidine groups were introduced to replace the 
3,4-dimethylisoxazole group and the thiazole ring, respectively.107 Notably, compound 74 (Figure 30) 
was exposed to exert potent inhibitory activity against human/rat FAAH (IC50 = 0.72/0.28 nM) and 
produce analgesic potency in both the spared nerve injury (SNI)-induced neuropathic pain and CFA-
induced inflammatory pain models in rats at 3 mg/kg doses (oral administration).107 
5. Boronic acids 
Boronic acid-based derivatives have been considered as potential pharmaceutical candidates and 
demonstrated to potently and reversibly inhibit several serine enzymes.108 In 2008, boronic acids were 
determined to inhibit FAAH.109 The para-substituted hydrophobic or electron-withdrawing groups of 
phenylboronic acids were shown to be advantageous for the inhibitory activity against FAAH. Notably, 
(4-nonylphenyl) boronic acid 75 (Figure 31a) exerted potent FAAH inhibitory capacity (IC50 (rFAAH) = 
9.1 nM). Exemplified by compound 75, molecular modeling with FAAH assumed that the two hydroxyl 
groups of 75 were able to form hydrogen bonds with Met191 and Ser193, respectively. The electrophilic 
boron atom was hypothesized to interact covalently with the nucleophilic hydroxyl group of Ser241 
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because of its trigonal planar sp2-hybridization and its empty p orbital.109 The covalent interaction between 
75 and Ser241 was presumed to form a reversible tetrahedral intermediate (Figure 31b).109 According to 
recent research on molecular binding simulation of FAAH,30,34 it was hypothesized that 4-nonylphenyl 
might be located in the ABP. Although the binding mechanism between boronic acid-based inhibitors and 
FAAH is still not clear, the remarkable inhibitory efficacy makes boronic acids useful chemical tools to 
further elucidate the catalytic mechanism of FAAH. However, boronic acid derivatives have been shown 
to suppress multiple serine enzymes, which could be a disadvantageous property for pre-clinical 
applications.109 
6. Arylthioheterocycles 
Most recently, a series of arylthioheterocycle-based non-covalent FAAH inhibitors were disclosed 
by Merck.110,111 According to the creation of a short-lived complex between non-covalent inhibitors and 
FAAH, they are expected to decrease potential risk factors over the formation of a long-lived covalent 
adduct. The development of arylthioheterocycle-based FAAH inhibitors was derived from an HTS hit 76 
(Figure 32). However, compound 76 manifested moderate FAAH inhibitory activity (IC50 = 119 nM) and 
poor pharmacokinetic parametres.111 To improve the inhibitory potency and pharmacokinetic properties, 
structural modifications of 76 were carried out.111 Structure-activity relationships indicated that use of an 
ether, sulfone, or sulfoxide instead of a thioether as the linker between the aromatic group and heterocycle 
ring resulted in a dramatic loss of inhibitory activity (Figure 32).111 The introduction of a phenyl, a para-
fluorophenyl or a pyridine group to the N-1 of the pyrazole and the replacement of the dioxane ring with 
a methyl sulfone or a 1,2,4-oxadiazole led to an improvement to the FAAH inhibitory potency (17 ≤ IC50 
≤ 32 nM, Figure 32). Finally, the oxazole analogue 77 (MK-4409, Figure 32) bearing the optimized 
substituents, a 4-pyridyl tertiary alcohol, a para-fluorophenyl and a thiopyridine, drastically improved the 
pharmacokinetic properties. The profile of analgesic effects in numerous models illustrated that the 
oxazole-based derivative 77 reduced inflammatory pain in a CFA model at a 10 mg/kg oral dose and 
attenuate neuropathic pain in a SNL model at a 3 mg/kg oral dose with a long duration of action until 24 
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h post-dose, and no apparent side effects were observed up to a dose of 100 mg/kg.111 The clinical trials 
data of 77 will be reported in due course. Compound 77 has been presumed to reversibly interact in a non-
covalent manner with FAAH. It can be used for further studies of non-covalent binding mechanisms with 
FAAH.111 
In addition, arylthioheterocycle derivatives were developed as PET tracers, which could be used for 
imaging FAAH in brain.110 The exploration was based on a lead compound 78 (Figure 33), which was 
previously identified as a potent FAAH inhibitor.110 However, compound 78 possessed an unfavorable 
lipophilicity (LogD = 4.2 at pH 7.3) complicating the in vivo PET studies in rhesus monkeys. To optimize 
lipophilicity and brain penetration, several modifications were performed.110 Notably, compound 79 (MK-
3168, Figure 33), possessing an ideal hydrophilic parameter (Log D = 3.3 at pH 7.3), was revealed to 
remarkably inhibit rat, rhesus, and human FAAH (IC50 = 1.0, 5.5 and 1.7 nM, respectively).110 The isotope 
labeled compound 79 could be used for the study of FAAH by imaging and for pharmacokinetics. 
7. 3-Carboxamido-5-arylisoxazoles 
A new series of FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold was disclosed 
in 2011.112, 113 The pharmacological results indicated that a 4-biphenyl ring at the 5-position of the 
isoxazole and N-substituted 2-(benzo[d][1,3]dioxol-5-yl)ethyl provided the optimal inhibitory efficacy.112 
Compound 80 (Figure 34) exerted potent capacity to suppress FAAH (IC50 = 88 nM) and produced 
protective efficacy and anti-inflammatory potency in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in mice at a 10 mg/kg oral dose.112 The molecular modeling of compound 80 suggested  that its 
isoxazole and carboxamide moieties  interact with the oxyanion hole, and form hydrogen bonds with 
Ile138 and Lys142, respectively. The rigid biphenyl group was assumed to establish a π-π interaction with 
Phe194. Additionally, the benzodioxole group was presumed to serve as a hydrogen bond acceptor and 
bind to Gln273.112 
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It was noteworthy that a series of CB2 agonists were concurrently explored based on the same 3-
carboxamido-5-arylisoxazole scaffold.113 Interestingly, during the exploration of CB2 agonists, some 
compounds were found to be more potent as FAAH inhibitors.113 For instance, compound 81 (Figure 34) 
was demonstrated as a potent CB2 agonist. Nevertheless, modification of the phenyl ring substituents 
revealed that a shift of the pentoxy group from the ortho position to the para position gave rise to a 
complete loss of CB2 agonism. Correspondingly, compound 82 (Figure 34) with a para-pentoxy 
substituent was discovered to drastically inhibit FAAH, compared with a modest FAAH inhibition of its 
meta analogue.113 Moreover, compound 82 was determined to exhibit anti-inflammatory efficacy in 
dextran sulfate sodium (DSS)-induced acute colitis in mice at a 10 mg/kg intraperitoneal dose.113 Overall, 
the 3-carboxamido-5-arylisoxazole could be a favorable scaffold used for the exploration of FAAH 
inhibitors or CB2 agonists. 
8. 1,3,4-Oxadiazol-2-ones 
1,3,4-Oxadiazol-2-ones were initially reported to reversibly inhibit several EC hydrolases, such as 
FAAH and MAGL.114 For example, compound 83 (Figure 35) exhibited remarkable FAAH inhibitory 
potency at nanomolar doses (IC50 = 6.1 nM), and approximately 20-fold selectivity over MAGL (IC50 = 
0.11-0.38 µM).114 To further improve the potency and selectivity, the exploration of N- and O-substituted 
phenyl groups was carried out.115 It was demonstrated that 1,3,4-oxadiazol-2-ones could be modified to 
fit either FAAH or MAGL by focusing on the different distinct characteristics of the catalytic center 
between FAAH and MAGL.115 Recently, Patel and co-workers made a breakthrough in the improvement 
of the selectivity of 1,3,4-oxadiazol-2-ones. They hypothesized that the poor selectivity of previously 
prepared 1,3,4-oxadiazol-2-ones could be attributed to the directly linked phenyl-oxadiazole moiety.116 In 
this case, a chiral carbon linker was introduced between the phenyl ring and oxadiazole group to give 
molecular flexibility.116 Structure-activity relationships illustrated that the chiral carbon linker (84, IC50 = 
23 nM) provided enhanced inhibitory potency against FAAH in comparison with the achiral methylene 
linker (85, IC50 = 91 nM). Moreover, the S-isomer (86, IC50 = 11 nM) was determined to show superior 
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potency, as compared to its enantiomer (IC50 = 240 nM).116 Typically, compound 86 (JZP-327A, Figure 
35) manifested optimal FAAH inhibitory potency and high selectivity over MAGL and COX isoenzymes. 
An ABPP assay indicated that 86 showed no off-target activity against other serine hydrolases (such as 
MAGL, ABHD6/12).116 Compound 86 was identified as a reversible FAAH inhibitor, according to the 
recovery of enzyme activity after a rapid dilution.50,116 Molecular modeling revealed the 1,3,4-oxadiazol-
2-one core establishes a strong H-bond network with the oxyanion hole of FAAH.116 The introduction of 
a chiral carbon linker could encourage the development of new selective FAAH inhibitors. The 1,3,4-
oxadiazol-2-one might be considered as a privileged scaffold for the further development of FAAH 
inhibitors, given the favorable strong interactions between 1,3,4-oxadiazol-2-ones and FAAH. 
9. Other FAAH inhibitors 
Apart from these interesting scaffolds mentioned above, a number of miscellaneous structures were 
disclosed to inhibit FAAH. 
Compound 87 (Figure 36), discovered at Abbott, was hypothesized to reversibly and non-covalently 
inhibit FAAH in the nanomolar range (IC50 (rFAAH) = 18 nM).117 The determination of selectivity by 
ABPP indicated that compound 87 exerted no off-target activity against numerous enzymes (such as TGH, 
KIAA1363, and carboxy esterases).117 
A series of non-covalent and reversible FAAH inhibitors was disclosed by Amgen in 2011.118 
Typically, compound 88 (Figure 36) exerted potent capacity to disable FAAH-mediated hydrolysis. As 
exemplified by compound 88, the X-ray crystal structure of 88-FAAH adduct indicated that the 4-(2,3-
dihydrobenzofuran-2-yl) substituent was located in the MAC, while piperidine moiety occupied the 
ABP.118 Additionally, van der Waals interactions were present between the pyrimidine and several 
hydrophobic residues of FAAH, including Phe432, Leu433, Met436, Thr488, Ile491, and Trp531. (Figure 
37)118,119 Compound 88 was determined to possess favorable pharmacokinetic parameters, including low 
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clearance rate, suitable bioavailability (92%) in rats and reasonable residence time (5.5 h after a 2 mg/kg 
dose).118 
Renovis, Inc. developed a series of tetrahydropyridopyridines as non-covalent and reversible FAAH 
inhibitors.120 Amongst these compounds, compound 89 (RN-450, Figure 36) exerted attractive FAAH 
inhibitory potency with IC50 of 13 nM and 25 nM towards human and rat FAAH, respectively.120 
Compound 90 (Figure 36) was disclosed to potently inhibit FAAH, but exhibited poor metabolic 
stability due to rapid reduction by a carbonyl reductase.121 
Compound 91 (MM-433593, Figure 36), a potent and selective FAAH inhibitor with an IC50 in the 
nanomolar range, was disclosed by Ironwood Pharmaceuticals Inc.122 It was determined to only slightly 
antagonize CB1 (IC50 > 1 μM) and be devoid of effects on CB2, COX1/2, FAAH-2, other serine hydrolases 
and a broad panel of receptors and channels.122 Although compound 91 has been shown to interact with 
FAAH in a non-covalent fashion, it was proposed to be an irreversible FAAH inhibitor.122 It is interesting 
to know the binding mechanism between 91 and FAAH. Probably, the non-covalent but irreversible 
property is attributed to the strong H-bonds interactions established between 91 and FAAH and/or the 
conformational change of FAAH induced by 91. The detailedbinding mechanism of 91 is expected to be 
disclosed. Moreover, compound 91 was shown to possess excellent pharmacokinetic parameters, 
moderate oral bioavailability (14-21%) in monkeys and a long half-life (17-20 h) post a 10 mg/kg oral 
dose or a 1 mg/kg intravenous dose.123 The detailed metabolic pathways and at least 18 metabolites of 91 
in monkey were described. Compound 91 will be further studied in human clinical trials.123 The discovery 
of 91 and its metabolic pathways in vivo is meaningful for the design and development of drug candidates. 
Moreover, a series of 1-aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanol derivatives as competitive 
FAAH inhibitors were reported by Johnson & Johnson.124 The extension of this series of FAAH inhibitors 
was encouraged by the HTS hit 92 (Figure 36). Interestingly, unlike α-ketoheterocycles, carbamates, or 
ureas, compound 92 does not possess any covalently reactive function that is intended to interact with 
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FAAH.124 The R-isomer of compound 92, rather than its S-isomer, was demonstrated to provide the 
principal inhibitory efficacy against FAAH (IC50 = 17 nM and 10 µM, respectively). Indeed, the hydroxyl 
group of the R-isomer was identified to be amenable to forming an H-bond with Thr488. In this case, the 
exploration was performed based on the R-isomer. Numerous aromatic groups were introduced to replace 
the trifluoromethoxyphenyl moiety appended to the pyrimidine ring.124 Generally, the compounds with 
substituted groups at the 2-position of the phenyl ring appended to the pyrimidine ring suffered from a 
substantial reduction of inhibitory capacity, whereas 3-/4-substituted hydrophobic groups contributed to 
the enhancement of inhibitory potency.124 Several compounds (such as compounds 93, 94, 95, and 96, 
Figure 36) exhibited remarkable capacity to block rat and human FAAH, although poor oral 
bioavailability and high clearance rate were detected in rats. Specifically, 3-chloro-4-
trifluoromethylphenyl substituted derivative 97 (JNJ-40413269, Figure 36) was shown to exert potent 
FAAH inhibition activity (IC50 = 5.3 nM) and advantageous pharmacokinetic properties including good 
oral bioavailability (94%), good brain penetration (brain/plasma ratio ~1), and prolonged half-life (t1/2 = 
4.1 h) in rats.124 Moreover, compound 97 was determined to produce a dose-dependent analgesic effect 
in a SNL model of neuropathic pain in rats post a 2/6/20 mg/kg oral administration.124 Compound 97 was 
modeled in a crystal structure of humanized rat FAAH, which indicated that the hydroxyl group appended 
to the chiral carbon possibly formed a hydrogen bond with Thr488.124 Given its advantageous 
pharmacokinetic properties, compound 97 might inspire the further development of reversible FAAH 
inhibitors. 
NAAA inhibitors 
1. Substrate inspired inhibitors 
Inspired by the structure of natural substrates, a series of PEA analogues were initially disclosed to 
inhibit NAAA. The PEA analogue-based inhibitors contain a hydrophobic side chain and a reactive 
functionality, such as an amide, reverse amide, ester, reverse ester, or amino group. N-
Pentadecylcyclohexanecarboxamide 98 (Figure 38) and N-pentadecylbenzamide 99, belonging to first 
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generation NAAA inhibitors, were revealed to inhibit rat lung NAAA.125 However, compound 98 was 
found to be unable to inhibit NAAA at 100 μM concentration, when it was resynthesized by Yamano and 
co-workers.126 Eventually, pentadecylamine 100, an impurity detected in the first batch of 98, was 
identified to strongly inhibit rat lung NAAA (around 90% inhibition) at 100 μM. Thus, the inhibitory 
activity of 99 is also uncertain and needs to be reevaluated, due to its similar chemical structure to 98. 
According to this interesting discovery, a series of lipophilic amines derived from 100 was developed by 
Yamano and co-workers.126 Especially, tridecyl 2-aminoacetate 101 (Figure 38) showed approximately 
90% inhibition of rat lung NAAA at 100 μM via competitive mechanism (examined by a Lineweaver–
Burk plot).126 The lipophilic amines might be protonated in solution while they were determined to inhibit 
NAAA at pH 5, the optimal catalytic pH of NAAA. Since the protonated and non-protonated molecules 
interact with enzymes through different mechanisms, the selectivity over FAAH was evaluated at both 
pH 5 and pH 8.5, a suitable pH for FAAH. The result indicated that there was no detectable inhibitory 
activity against FAAH at pH 8.5, whereas compounds 100 and 101 slightly inhibited rat FAAH at pH 5 
at a concentration of 100 μM.126 
Moreover, the cyclobutyl palmitate 102 and cyclopentyl palmitate 103 compounds (Figure 38) were 
determined to block human recombinant NAAA at a concentration of 50 μM with 41% and 85% inhibition 
of NAAA activity, respectively.127 Compound 103 was observed to drastically elevate PEA levels in intact 
HEK-NAAA cells without affecting the AEA and OEA signaling at 50 μM.128 Furthermore, topical 
administration of compound 103 (200-400 μg/sponge, 1.5 cm3) in a model of carrageenan-induced 
inflammation in rats, was found to reduce inflammation.128 
Compound 104 (Figure 38) was reported to be a weak dual inhibitor against NAAA and FAAH.129 
The replacement of the pyrrolidine ring with other cyclic functions led to a dramatic decrease of inhibitory 
potency against NAAA. The introduction of a biphenyl group on the acyl chain produced compound 105 
(Figure 38), which potently inhibited rNAAA selectively vs. rFAAH (IC50 = 2.12 µM and > 100 µM, 
respectively).129 Furthermore, the optimal substrate-based NAAA inhibitor 106 (AM9023, IC50 = 0.6 μM, 
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Figure 38) to date was revealed.130 The isothiocyanate moiety of 106 was determined to interact reversibly 
with the cysteine of the enzyme catalytic triad by kinetic studies and using mass spectrometry. Compound 
106 displayed moderate selectivity for human NAAA over human MAGL and rat FAAH (IC50 > 10 
μM).130 Indeed, the electrophilicity of isothiocyanate enables it to interact with serines, cysteines, and 
amino groups in biomolecules. Therefore, isothiocyanate can be considered as an interesting scaffold for 
drug design. However, off-target effects of isothiocyanates should be considered with attention due to 
their highly reactive properties. 
Overall, most substrate-based NAAA inhibitors only exert modest inhibitory activity and selectivity. 
Typically, compound 106 exhibits the optimal inhibitory potency, which could be used for the further 
research of interactive mechanisms with NAAA. 
2. β-Lactones 
The presence of the catalytic triad in NAAA has encouraged the development of a series of 
electrophilic function-dependent NAAA inhibitors. Since the nucleophilic reactive sulfhydryl cysteine 
group of NAAA was found to interact with the electrophilic carbonyl group of substrates during catalysis, 
the presence of the electrophilic function was proposed to provide inhibitory potency through the 
formation of a covalent bond with the thiol group. In this case, compounds with electrophilic functions 
were expected to be developed. 
Compound 107 (Figure 39), a serine-derived β-lactone, was initially reported to inhibit the cysteine 
protease hepatitis A Virus 3C protease. Afterwards, compound 107 was discovered to inhibit NAAA.7 In 
this case, the β-lactone ring rather than the carbamate moiety appears to covalently bind to the NAAA 
active site, based on the structure-activity relationships showing that the removal of the β-lactone gives 
rise to a complete loss of potency.7,131 Removal of the oxygen atom of the carbamate moiety produced 
compound 108 ((S)-OOPP, Figure 39), which exerted an approximately 7-fold increase in inhibition, in 
comparison with compound 107 (IC50 = 0.42 and 2.96 μM, respectively).7,131 Interestingly, the (R)-
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enantiomer of 108 displayed a markedly lower inhibition with respect to its (S)-enantiomer (IC50 = 6 μM). 
Kinetic analyses disclosed that 108 interacted with NAAA through a non-competitive mechanism.7 
Compound 108 showed high selectivity for human NAAA over acid ceramidase and one kind of cysteine 
hydrolase that is very similar to the structure and function of NAAA. In addition, compound 108 was 
determined to be devoid of inhibitory potency against FAAH or other serine hydrolases.7 Furthermore, 
compound 108 was shown to reduce neutrophil migration and alleviate injury in a model of traumatic 
spinal cord injury in mice (30 μg per mouse, intrathecal injection).7 However, lack of stability in plasma 
(half-life < 1 min)7 makes 108 a poor drug candidate for systemic application. To further improve potency 
and stability, the exploration of β-lactone-based NAAA inhibitors was performed (Figure 40). The 
replacement of the phenethyl ring with a hexyl chain maintained the capacity to inhibit NAAA (compound 
109, IC50 = 460 nM).131 The introduction of lipophilic groups, such as naphthyl or biphenyl groups, was 
shown to be advantageous for inhibitory potency. Specially, compound 110 (Figure 40) exerted the 
optimal inhibitory efficacy against NAAA. Compound 110 was purported to covalently and reversibly 
bind to NAAA according to a slow recovery of enzyme activity following 12-hour dialysis. In addition, 
compound 110 was reported to possess non-competitive inhibitor property that the increase of 110 
concentration did not affect Km but induced a decrease of Vmax.131 Compound 110 was shown to reduce 
carrageenan-induced inflammation post a 10 μL/sponge (1 cm3) topical administration.131 Mass 
spectrometry studies supposed that the nucleophilic thiol group of the Cys131 of rat NAAA interact the 
carbonyl of β-lactone group to form an acyl-NAAA intermediate.7,131,132  
The β-lactone group has been shown to react readily with nucleophiles, and can be rapidly 
hydrolyzed in aqueous solution. In fact, most amide-based β-lactone derivatives were rapidly hydrolyzed 
in aqueous buffer at pH 7.4 with half-lives of less than 20 minutes, whereas the β-substituted methyl group 
endowed the β-lactone derivatives with improved stability (half-life > 70 min).133 Afterwards, urea- and 
carbamate-based β-lactone derivatives were identified to possess drastically increased chemical stability 
at both pH 5 and pH 7.4 in comparison with the corresponding amide-based β-lactone derivatives.133 
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Structure-activity relationships revealed that the (R)-configuration of carbamate-based β-lactones was 
favorable for inhibitory capacity, whereas the (S)-configuration is suitable for urea-based β-lactones 
(Figure 40).133 Although these urea/carbamate-based β-lactones manifested improved chemical stability 
in buffer solution, they were rapidly eliminated in the presence of bovine serum albumin. In particular, 
tert-butoxycarbonyl substitution increased the compounds’ stability in the presence of bovine serum 
albumin (t1/2 ~2 h) and retained moderate inhibitory potency.133 Nevertheless, they still possessed poor 
stability in rat plasma (t1/2 < 1 min). Chemical structure optimization gave rise to a potent NAAA inhibitor, 
compound 111 (URB913/ARN077, Figure 39), which manifested the optimal inhibitory efficacy against 
rat and human NAAA (IC50 = 0.05 and 0.007 μM, respectively) and enhanced chemical stability in buffer 
solution (t1/2 > 110 min).133,134 Furthermore, compound 111 was shown to protect PEA and OEA from 
hydrolysis in mice ear skin post a topical administration (10% in acetone). It attenuated inflammation in 
a model of carrageenan-induced edema post a topical administration (30% in petrolatum/5% lauric acid) 
through the stimulation of PPAR-α, due to the blockage of anti-inflammatory effect in PPAR-/- deficient 
mice.135 Compound 111 rapidly, non-competitively, covalently and reversibly combined with rat NAAA, 
whereas the inhibition of human NAAA was only partially reversible.132 The binding mechanism studies 
indicated that the thiol group of the active cysteine (Cys131 for rat NAAA, Cys126 for human NAAA) 
interacted with the carbonyl of β-lactone moiety of 111 to form a hydrolysable thioester bond (Figure 
41).132 Further investigation of the selectivity of 111 indicated that it was devoid of off-target effects in a 
panel of several targets including GPCRs, enzymes, transporters, and channels at a 10 μM concentration.40 
Due to the instability of compound 111 in plasma, it was administrated topically rather than systemically 
in mouse models of inflammation and nerve injury. The compound (10% in acetone) was effective in 
TPA-induced edema and CCI mouse models.135 
Modification of the phenylpentyl moiety of 111 was performed. Removal of the phenyl ring or 
modification of the carbon chain length of the phenylpentyl group appeared to result in a notable decease 
of inhibition (Figure 42).134 However, the extension of the alkyl chain after the removal of the phenyl ring 
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brought about a recovery of inhibitory ability. Especially, the aliphatic chains with 7-8 carbon atoms 
length (112 and 113, IC50 (rNAAA) = 0.04 and 0.03 μM, respectively, Figure 42) provided a slight 
increase of inhibitory potency in comparison with 111. The replacement of the phenyl ring with the 
cyclohexyl group (114, Figure 42) led to an enhancement of inhibitory efficacy (IC50 (rNAAA) = 0.013 
µM). Moreover, the replacement of a carbon in the alkyl chain of 111 with an oxygen atom was 
tolerated.134 It was noteworthy that 115 (Figure 42) displayed optimal inhibitory potency in the single-
digit nanomolar range against both rat and human NAAA (IC50 = 0.007 µM), whereas its m-
biphenylmethyl analogue was determined to only slightly inhibit rat NAAA (IC50 = 23 μM).134 Compound 
115 showed no inhibitory activity against rat FAAH at 10 μM concentrations, whereas, it was observed 
to slightly inhibit rat acid ceramidase with 30% inhibition at the same concentration.134 
Further modification of the β-substituent on the β-lactone ring of NAAA inhibitors was carried out 
to improve their stability.136 In general, carbamate-based β-lactones exhibited enhanced inhibitory 
potency and improved chemical stability in comparison to urea-based β-lactone derivatives.136 Bulky 
alkyl substituents (such as isopropyl and tert-butyl) at the β-position of the β-lactone ring resulted in 
improved chemical stability in buffer solution, although this resulted in a decrease of inhibitory efficacy 
against human NAAA (IC50 = 0.063 and 0.302 µM, respectively, Figure 42).136 Most β-lactone derivatives 
exerted poor plasma stability with a half-life less than 5 min. Notably, compounds 116 and 117 (IC50 
(hNAAA) = 0.234 and 0.507 µM, respectively) (Figure 42) possessed improved stability in plasma with 
a half-life greater than 5 min and exerted modest inhibitory potency against NAAA.136 Although the result 
indicated that it was difficult to find a functional group providing both desirable stability and potent 
NAAA inhibitory potency for β-lactone derivatives, this investigation of stability could be considered as 
a favorable starting point for further development of NAAA inhibitors with suitable chemical and 
metabolic stability. 
Most recently, the first three dimensional quantitative structure-activity relationship (3D-QSAR) 
model was established based on the (2-methyl-4-oxooxetan-3-yl)carbamate-derived NAAA inhibitors to 
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predict chemical structures that probably inhibit NAAA.137 This model was established using a training 
set comprising 33 compounds and the Atomic Property Fields method. The squared correlation 
coefficients between the experimental pIC50 and the predicted pIC50 is 0.93 and the leave one-out squared 
correlation coefficients Q2 is 0.69. Afterwards, 5 predicted compounds were used to valid this model. The 
experimental pIC50 of these 5 compounds were found to be very close to the predicted values.137 This 
model has already been used to discover several potent NAAA inhibitors (such as 118 and 119, Figure 
39)., Compound 118 blocks the catalytic activity of NAAA in the nanomolar range.137 From this 3D-
QSAR model, the linear symmetrical structure of the aliphatic side chain appears to be advantageous for 
the inhibitory capacity against NAAA. This 3D-QSAR model is meaningful for the further design and 
prediction of potent NAAA inhibitors. 
3. β-Lactams 
Exploration of β-lactams as NAAA inhibitors was inspired by the structure of β-lactone-based 
inhibitors. Since the β-lactone moiety was identified to be unstable in plasma, its replacement with a more 
stable functionality was required and this was demonstrated to dramatically enhance the stability in 
plasma.138 Structure-activity relationships indicated that the linear acyl chain seemed to be favorable for 
the inhibitory capacity of β-lactams against NAAA. For instance, the amide-based β-lactams with a 9 to 
11 carbon length acyl chain (120, 121, 122 and 123) and the carbamate-based β-lactam with a 7-carbon 
length O-alkyl chain (124) exerted potent activity against NAAA (Figure 43).138 The (S)-configuration 
rather than the (R)-configuration at the C3 position of the amide function is suitable for β-lactam-based 
NAAA inhibitors.138 For example, compound 120 exerted potent inhibitory activity against human NAAA 
without affecting human FAAH-mediated hydrolysis and possessed good oral bioavailability (67%) in 
rats.138 Overall, the significantly improved stability affords β-lactams the potential for systemic 
application. 
Furthermore, compound 124 encouraged the development of carbamated-based β-lactams as potent 
NAAA inhibitors. Most recently, compound 125 (ARN726, Figure 43) was shown to markedly inhibit 
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both rat and human NAAA (IC50 = 63 and 27 nM, respectively) with approximately 9-fold enhanced 
activity in comparison with compound 124 (IC50 (hNAAA) = 0.24 µM).139  Nevertheless, the R-isomer of 
125 showed weak affinity for NAAA (IC50 = 3.1 µM). Compound 125 was determined to covalently and 
irreversibly interact with NAAA by mass spectrometry and dialysis studies, which indicated that the 
cysteine thiol group of NAAA interacted with the amide group of β-lactam moiety to generate the acyl-
NAAA adduct (Figure 44).139 Compound 125 was devoid of effects against rat FAAH and only marginally 
inactivated rat acid ceramidase. Compound 125 was further determined to have no effect on a panel of 28 
biological targets including lipid-hydrolyzing enzymes and 79 common targets comprising ion channels, 
membrane transporters and receptors (such as cannabinoid receptors) at a concentration of 10 μM.139 
Pharmacokinetic analyses revealed that 125 was rapidly eliminated in vivo (Cmax = 1608 ng/kg in plasma 
with a t1/2 ~15 min, and clearance = 139 mL min-1 kg-1) post a 3 mg/kg intravenous dose in mice. These 
data were consistent with the ex vivo assay that 125 was efficiently eliminated in plasma (a t1/2 of 41 min 
in mice and 12 min in rats) and in liver microsomes (a t1/2 less than 5 min in both rats and mice). 
Nevertheless, the inhibition of NAAA-mediated hydrolysis in several organs was detected after 
intraperitoneal administration of 125 (3-30 mg/kg). For instance, the covalent adducts of NAAA-125 were 
detected by mass spectrometry in mice lungs139 Notably, compound 125 was disclosed as the first β-
lactam-derived NAAA inhibitor for systemic application. It reduced inflammation (30 mg/kg oral dose) 
in a model of carrageenan-induced inflammation in mice. Compound 125 possessed a short plasma t1/2 
but exerted profound anti-inflammatory efficacy in vivo, which might indicate that NAAA-dependent 
modulation of anti-inflammation is efficient. The disclosure of 125 may encourage the exploration of β-
lactam-based NAAA inhibitors with suitable properties for systemic administration. 
More recently, the optimization of the β-lactam moiety or the side chain of carbamate-based β-
lactams was carried out.140 The investigation of structure activity-relationships disclosed that a linear and 
lipophilic side chain is favorable for NAAA inhibitory capacity, and (S)-configuration is preferred rather 
than its (R)-isomer. Specifically, compounds 126, 127 and 128 (Figure 43) possessed encouraging 
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inhibitory potency towards NAAA (IC50 = 12 nM, 7 nM, and 22 nM, respectively, evaluated by 
UPLC/MS-based assay). These three compounds were determined to be devoid of activity against FAAH 
and display a moderate selectivity ratio over human acid ceramidase (50 < SI < 400) at 10 μM. In addition, 
compound 128 manifested a superior stability (half-life ≥ 25 min in rat plasma and rat/mouse liver) in 
comparison to 125. Its metabolic stability is probably attributed to the phenyl ring adjacent to carbamate 
moiety. Its pharmacological properties will be disclosed in due course.140 
Generally speaking, β-lactams can be considered as a more suitable scaffold than β-lactones for the 
investigation of NAAA inhibitors, according to their relatively stable chemical structure. Although some 
β-lactam-derived NAAA inhibitors described herein (e.g. compounds 126, 127 and 128) have been 
demonstrated not to affect FAAH, β-lactam derivatives have also been described as FAAH inhibitors.141 
Thus, the selectivity of β-lactams over NAAA or FAAH needs to be investigated. According to related 
data, structure-activity relationships are summarized in Figure 45. As illustrated, the R2 group plays a 
crucial role in selectivity over NAAA or FAAH. Alkylation of the N-H function of β-lactam brings about 
a complete loss of NAAA inhibitory activity, whereas removal of R2 group results in a sharp decrease of 
FAAH inhibitory activity. The different structural preference for a β-lactam-derived NAAA and FAAH 
inhibitor is probably due to their different binding mechanism. Indeed, the β-lactam moiety was predicted 
to form H-bonds with FAAH, whereas the β-lactam was identified to covalently react with NAAA.139,141 
Hence, the reactive secondary β-lactam function rather than tertiary β-lactam is preferred for NAAA. 
4. Other NAAA inhibitors 
In a recently published paper, compound AM9053 (structure not disclosed, IC50 = 30 nM) was 
revealed as one of the first systemically active NAAA inhibitors that increased PEA rather than AEA 
levels in a model of inflammatory bowel disease (IBD) in mice.142 It showed excellent selectivity over 
FAAH (IC50 > 100 μM) and produced PPAR-α-dependent anti-inflammatory effect, including the 
inhibition of pro-inflammatory cytokines (e.g. TNF-α, IL-1β) expression, in a model of TNBS-induced 
colitis post a 10 mg/kg intraperitoneal dose in mice.142 
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Compound 129 (diacerein, Figure 46), is an approved medicine for alleviating osteoarthritis 
(swelling and pain in the joints) through the inhibition of IL-1β.143 Recently, it was shown to display time-
dependent inhibition of human NAAA (IC50 = 0.7-7.2 μM) in both the cell-free enzyme and intact cells.144 
Compound 129 showed no interaction with rat FAAH, human cannabinoid receptors (CB1 and CB2), and 
human TRPV1 receptors at a 50 μM concentration.144 It was determined to alleviate inflammation and 
hyperalgesia with a long duration of action (> 6 h) in a carrageenan-induced acute inflammatory pain 
model in rats post a 25 mg/kg oral dose.144 Although 129 has been shown to inhibit NAAA in vitro, 
produce anti-inflammation and elevate PEA levels in a carrageenan-induced acute inflammatory pain 
model, further investigated is needed in order to ascertain whether 129-mediated anti-inflammation and 
increase of PEA levels can be specifically attributed to NAAA inhibition. In summary, the discovery of 
129 as a potent NAAA inhibitor might encourage the development of new scaffold-based NAAA 
inhibitors with suitable duration of action for systemic administration. Compound 129 could be a useful 
tool for the investigation of other probable mechanisms in addition to the inhibition of IL-1β-dependent 
activities in vivo. 
Most recently, compound 130 (F96, Figure 46) was revealed to be a potent inhibitor of NAAA and 
have excellent chemical stability in buffer solution with a half-life of more than 24 hours, and dramatically 
improved metabolic stability in rat plasma with a half-life of nearly 200 min.145 Compound 130 exhibited 
high selectivity for NAAA over FAAH and almost no activity against MAGL or acid ceramidase at a 10 
μM concentration in vitro and was devoid of affinity for cannabinoid receptors and PPAR-α. The anti-
inflammatory and anti-nociceptive effects of 130 can be reversed by a PPAR-α antagonist (1-[(4-
chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,α-dimethyl-5-(1-methylethyl)-1H-indole-2-
propanoic acid, MK886) but not by cannabinoid receptor antagonists 1 and rimonabant (131, Figure 47), 
which led to the conclusion that 130 produced anti-inflammation and analgesia through a PPAR-α-
dependent activity rather than cannabinoid receptors.145 It is noteworthy that 130 elevated PEA levels via 
inactivation of NAAA without the alteration of AEA signaling. Compound 130 alleviated pain and 
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inflammation (10 mg/kg intraperitoneal injection) in several animal models including 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced ear edema, sciatic nerve injury-induced neuropathic 
pain, and acetic acid-induced visceral pain in mice.145 
Compound 130 showed less toxicity than ibuprofen (a widely used anti-inflammatory and anti-
nociceptive drug) in zebrafish models.145 Further investigation is needed to establish whether 130 is 
devoid of severe side effects in other in vivo animal models (e.g. mammals). In general, compound 130 
possesses potent NAAA inhibitory efficacy and suitable metabolic stability in plasma. The advantageous 
properties of 130 might encourage the further development of NAAA inhibitors with a long duration of 
action in vivo. The investigation of the binding mechanism between 130 and NAAA is expected to be 
carried out in the future. 
MAGL inhibitors 
Generally, MAGL is sensitive to some early described serine hydrolases inhibitors, such as 
compounds 2-4,45 although these compounds usually manifest off-target potency against other serine 
hydrolases (such as FAAH). With respect to other serine hydrolases, MAGL has been demonstrated to 
additionally interact with sulfhydryl-sensitive substrates in line with its structural features as it contains 
several active cysteine residues (such as Cys201, Cys208, and Cys242).46 This property was regarded as 
the starting point for the development of selective MAGL inhibitors over other serine hydrolases. 
1. Maleimides 
First generation MAGL inhibitors were described several decades ago. Some inhibitors, such as N-
ethylmaleimide 132 (Figure 48a), comprise mercapto-specific functions. Moreover, a series of maleimide 
derivatives were identified to inhibit MAGL via a Michael addition with cysteine residue thiol groups by 
mass spectrometry and mutational analysis.46,146 Structure-activity relationships indicated that N-
substituted hydrophobic groups of maleimide derivatives have improved inhibition against MAGL in 
comparison with N-hydrophilic substituents.46 Especially, compounds 133 (IC50 = 0.14 µM) and 134 (IC50 
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= 9.2 µM) exerted approximately 6-fold and 380-fold enhanced potency against MAGL-like enzyme in 
rat cerebellar membranes, respectively, compared to 132 (IC50 = 53 µM, Figure 48a).46 The sulfhydryl 
group of cysteine residues was shown to interact covalently and irreversibly with the maleimide moiety 
through a Michael addition to yield a S-alkylated MAGL adduct (Figure 48b).146 Moreover, the 
modification of the N-substituent of 133 led to the identification of 135 (Figure 48a) as a moderate and 
selective inhibitor with an IC50 of 0.79 µM against hMAGL over hFAAH (SI > 20-fold).147 
2. Disulfides 
Compound 136 (disulfiram), an approved drug to treat alcoholism via suppression of aldehyde 
dehydrogenase, was reported to inhibit human MAGL at submicromolar concentrations (IC50 = 0.36 µM, 
Figure 49).148 Additionally, two disulfide derivatives, compounds 137 (IC50 = 1.6 µM) and 138 (IC50 = 
0.13 µM), were shown to inactivate MAGL-mediated activity in the micromolar range (Figure 49).148 
These disulfide derivatives were hypothesized to interact with the cysteine residues of MAGL to form a 
mixed adduct or a disulfide bond.148 The exploration of numerous analogs of 136 with different 
substitutions led to discovering a series of selective MAGL inhibitors. Typically, compound 139 (Figure 
49) exerted optimal inhibitory capacity against hMAGL with an IC50 of 0.11 µM and more than 1000-
fold selectivity over hFAAH.45,149 Compound 139 was presumed to interact irreversibly with MAGL, 
which might be accompanied by the formation of disulfide bond with cysteine.149  
3. Isothiazolinones  
Compound 140 (octhilinone, IC50 = 88 nM, Figure 50a) was reported to be a potent MAGL inhibitor 
by King and co-workers, when they investigated a series of sulfhydryl-specific candidates.150 It was 
shown to disable MAGL through a partially reversible mechanism, due to a recovery of enzyme activity 
after dilution. The introduction of a N-substituted long hydrophobic alkyl group (such as 141, IC50 = 43 
nM) or replacement of isothiazolinone moiety with benzisothiazolinone (142, IC50 = 20 nM) brought 
about a slight improvement of inhibitory potency (Figure 50a).150 To investigate a probable interactive 
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mechanism, studies using a reducing agent dithiothreitol (DTT) were performed. The addition of DTT 
appeared to block 140-induced inhibition of MAGL, but did not affect 3-mediated inhibition of MAGL. 
This finding indicated that 140, rather than 3, might form a reducible bond with MAGL, which was not 
consistent with the formation of a Michael addition product. Additionally, compound 142 exerted a 
comparable inhibitory activity to that of 140, which supported that isothiazolinone-induced inhibition of 
MAGL was not attributed to their ability to undergo a Michael addition. Compound 140 was proposed to 
form a disulfide adduct with MAGL (Figure 50b). Furthermore, mutation studies showed that Cys208 
rather than Cys201 or Cys242 played a crucial role in the reaction with compound 140.150 Isothiazolinone 
could be regarded as a favorable scaffold for the further exploration of potent MAGL inhibitors. 
4. Ureas 
Compound 50, which was originally reported as an AEA transporter inhibitor, was also shown to 
exert off-target effects against several carboxylases and serine hydrolases (such as FAAH and MAGL).3,89 
Indeed, a 2,5-regioisomer of 50 (compound 143, Figure 51) exhibited approximately 400 times more 
potent inhibition against MAGL-like enzyme in comparison to 50 (IC50 = 0.02 and 8.10 µM, 
respectively).151 Unfortunately, compound 143 exerted poor selectivity over FAAH expressed in rat brain 
membranes (IC50 = 0.033 µM). The investigation of its binding mechanism by mass spectrometry and 
mutational analysis showed that the hydroxyl group of Ser122 interacted with the urea moiety of 143 to 
produce a carbamylated-enzyme adduct, accompanied by the release of the biphenylmethyl tetrazole 
moiety (Figure 52).146 Moreover, Sanofi-Aventis disclosed a triazole urea 144 (SAR629, Figure 51) as a 
potent covalent MAGL inhibitor. Similar to compound 143, the urea moiety of 144 was determined by 
X-ray to interact with Ser122 of MAGL followed by the formation of a carbamylated-enzyme adduct 
(Figure 53), associated with the release of the triazole moiety. Compound 144-induced inhibition of 
MAGL is proposed to be quasi-irreversible due to the possible hydrolysis of 144-MAGL adduct by a 
water molecule. This hypothesis needs to be further examined.44 Over the last few years, the exploration 
of numerous urea-based MAGL inhibitors has been performed. For example, compound 145 (ML30, IC50 
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(hMAGL) = 0.54 nM, Figure 51) exerted a strong ability to irreversibly inhibit hMAGL in the 
subnanomolar range with more than a 1000-fold selectivity over FAAH.152 Recently, a series of 
piperazine/piperidine triazole ureas were described as highly selective MAGL inhibitors.153 Structure-
activity relationships illustrated that the Y-type scaffold of triazole ureas favors selectivity over FAAH.  
The replacement of the triazole moiety with a 4-nitrophenoxy group or the removal of a nitrogen of 
the triazole resulted in a dramatic decrease of inhibitory potency (Figure 54).153 Furthermore, compounds 
146 (JJKK-046) and 147 (JJKK-048) (Figure 54) were determined to inhibit hMAGL in the subnanomolar 
range (IC50 = 0.562 and 0.363 nM, respectively) and exert appreciable selectivity over several serine 
hydrolases, as shown using ABPP assays, including FAAH (SI > 1200 and 11200 fold, respectively), 
ABHD6 (SI > 150 and 600 fold, respectively). In addition, these two compounds exhibited no detectable 
potency against ABHD12 at a 1 μM concentration.153 In addition, compound 147, unlike 146, was 
disclosed to selectively elevate 2-AG levels without affecting AEA signaling at a concentration of 1 μM 
in rat brain.153 Indeed, the presence of a C=C bond was shown to favor the interaction with FAAH.34 The 
presence of a further C=C bond might make 146 less selective than 147 over FAAH. The discovery of 
147 could inspire the further development of highly selective MAGL inhibitors. 
More recently, Patel’s group disclosed a novel series of urea-based MAGL inhibitors derived from 
loratadine (Figure 51), a histamine H1 receptor antagonist.154 Specially, compounds 148 and 149 (JZP-
361, Figure 51) were determined to optimally and selectively inactivate human MAGL at submicromolar 
concentrations over human FAAH (SI > 140 folds and > 150 folds, respectively), human ABHD6 (SI ≈ 
38-fold and ≈ 19-fold, respectively), and human ABHD12 (no detectable inhibitory potency at a 10 μM 
concentration). Their inhibitory effects were determined to be slowly reversed after dilution.154 In 
addition, compound 149 exhibited no observable affinity for cannabinoid CB1 and CB2 receptors at 10 
μM concentration. However, both 148 and 149 maintained histamine H1 receptor antagonistic activities 
comparable to loratadine. As a novel dual-action agent, compound 149 is desirable to be profiled in a 
model of inflammation.154 
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5. Carbamates 
In 2005, Hohmann and co-workers profiled a series of N-biphenyl carbamates and revealed 150 
(URB602, Figure 55) as an inhibitor against MAGL with weak potency (IC50 = 28 µM),155 it was further 
identified to inhibit FAAH as an off-target.156 The finding that 150 elevates 2-AG levels without affecting 
AEA levels at a 100 μM concentration in rat brain slice cultures155 is probably due to the fact that more 
than 80% inhibition of FAAH is required for a detectable increase of AEA level.157 Compound 150 was 
determined to covalently but partially reversibly bind to MAGL by dialysis experiments. The O-
substituent of 150 was assumed to serve as the leaving group after hydrolysis.158 
The disclosure of a new series of carbamate-based MAGL inhibitors by Cravatt and co-workers was 
regarded as one of the most encouraging breakthroughs in this area.159 The profile of selectivity by ABPP 
assays led to the identification of 151 (JZL184, Figure 55) as a potent and selective MAGL inhibitor. 
Compound 151 was determined to inactivate MAGL-mediated activity at nanomolar levels and be devoid 
of off-target effect towards cannabinoid receptors and several serine enzymes (such as FAAH and 
ABHD6) at 1 μM concentration (IC50 (mMAGL) = 8 nM, IC50 (FAAH) = 4 µM).159 Despite exerting the 
suppression of FAAH at a 10 μM concentration in vitro and 16 mg/kg in vivo, compound 151 still showed 
no detectable effect on the accumulation of AEA levels.159 Indeed, this result is consistent with the 
previous demonstration that the observable elevation of AEA levels occurs in the case of more than 80% 
inhibition of FAAH.157 However, multidimensional protein identification technology (ABPP-MudPIT) 
assays implied that 151 inactivated esterase 1, esterase 1-like, and triacylglycerol hydrolase 2 as off-
targets.48 In addition, compound 151 was found to exert a long duration of action such that the increase 
of 2-AG signaling was detectable even 24 h post administration.159 The administration of 150 was shown 
to produce analgesic effects in several pain models, including acute thermal pain (16 mg/kg intraperitoneal 
injection), acetic acid-induced visceral pain writhing (16 mg/kg intraperitoneal injection), and formalin-
induced edema pain (40 mg/kg oral dose) in mice. Compound 151-induced anti-nociception was reversed 
by a CB1 antagonist (131). This observation indicated that 151-induced pain relief was mediated by CB1-
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dependent activities.159 The administration of 151 at high doses (40 mg/kg) rather than low doses (4 
mg/kg) gave rise to elevation of both AEA and 2-AG levels, which was accompanied by a decrease of 
body temperature and motility. These adverse effects following high-dose 151 treatment might be 
attributed to its off-target inhibition of FAAH, consistent with the previous finding that dual 
FAAH/MAGL inhibition produced cannabimimetic side effects.159,160 Furthermore, the administration of 
151 was demonstrated to produce gastroprotective and antidepressant-like effects post a 4 mg/kg 
intraperitoneal injection.160,161 The determination of the binding mechanism indicated that 151 covalently 
and irreversibly bound to MAGL through the formation of the carbamylated-enzyme adduct (Figure 56). 
Overall, compound 151 is a selective MAGL inhibitor that exerts multiple CB1-dependent protective and 
anti-nociceptive effects through the elevation of 2-AG levels in the nervous system. Compound 151 could 
be regarded as a useful tool for the further investigation of the functional roles of MAGL. Nevertheless, 
the selectivity of 151 is still improvable. The further repeated administration of high-dose 151 resulted in 
the alteration of both 2-AG and AEA levels.162 
Recently, Cravatt’s team reported a novel series of O-hexafluoropropyloxy carbamates as MAGL 
inhibitors.163 In comparison with 151, compounds 152 (KML29), 153 (JW618), and 154 (JW642) exerted 
superior selectivity over mFAAH in ABPP assays (Figure 55). Specifically, compound 154 only slightly 
inhibited mFAAH at a 10 μM concentration, whereas compound 151 almost completely inhibited 
mFAAH at the same concentration.159,163 Nevertheless, compound 154, unlike compounds 152 and 153, 
markedly inhibited mFAAH at a high concentration of 50 μM. Compound 152 inhibited ABHD6 at a 10 
μM concentration, whereas compounds 153 and 154 resulted in a significant inhibition of ABHD6 at a 
100 nM concentration. Thus, compounds 153 and 154 appear to be dual FAAH/ABHD6 inhibitors.163 It 
was noteworthy that 152 did not affect any serine hydrolases at a high dose of 40 mg/kg in mouse brain 
in ABPP studies. Moreover, compound 152 was determined to exhibit no off-target effects against any 
carboxylesterases even at 40 mg/kg concentrations in mouse liver in ABPP studies. On the contrary, 
compound 151 was observed to inhibit several carboxylesterases including esterase 1 and esterase 1-
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like.48,163 Compound 152 only slightly inhibited carboxylesterase 1 as an off-target in mouse lung. 
Furthermore, compound 152 was determined to give maximal inhibition of MAGL in the brain by 1 h 
post-dose and such inhibitory action was still detectable 24 h post-administration.163 Like most of 
carbamate-based MAGL inhibitors, compound 152 was shown to covalently and irreversibly interact with 
MAGL along with the formation of the carbamylated-enzyme adduct and the release of a 
hexafluoropropyloxy group. Compound 152 exerted antinociceptive effects in a wide range of pain 
models (such as carrageenan-induced inflammatory pain and CCI neuropathic pain) post a 20-40 mg/kg 
intraperitoneal injection without resulting in cannabimimetic side effects including hypomotility, 
hypothermia and catalepsy.164 Its administration was accompanied by a dramatic elevation of 2-AG levels 
and was devoid of alteration of AEA, PEA, OEA levels in mouse brain. In addition, it was shown to 
alleviate NSAID (e.g. diclofenac sodium)-induced gastric injury (haemorrhages) after a 40 kg/mg 
intraperitoneal injection. Compound 152-induced gastro-protective effects were later identified to be CB1 
rather than CB2-dependent, since this protective action was blocked by a CB1 antagonist 131 but not by 
the CB2 antagonist 1 (3 kg/mg intraperitoneal injection)164 More recently, compound 152-induced 
accumulation of 2-AG was revealed to be tissue-dependent. Indeed, the most pronounced elevation of 2-
AG levels was observed in the brain and spinal cord.165 This observation indicated that 152-mediated 
activity was more CNS-dependent. Compound 152 could be regarded as a promising agent for the therapy 
of CNS-related disorders.165 
In 2013, the screening of O-substituents of benzhydrylpiperazine carbamates by Cravatt and co-
workers led to the identification of 155 (JW651) and 156 (MJN110) as potent selective MAGL inhibitors 
as shown using in vitro/in vivo competitive and click chemistry ABPP (Figure 55).166,167 Compound 155 
was determined to markedly inhibit MAGL at a 0.1 μM concentration in vitro and almost completely 
inactivate MAGL at low doses (5 mg/kg) in mouse brain. Apart from the inhibition of ABHD6 at 10 μM 
concentrations in vitro and 40 mg/kg doses in vivo, no off-target effect was detected even at high 
concentrations of 100 μM and a high dose of 40 mg/kg.166 Replacement of the hexafluoropropyloxy group 
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of 155 by a succinimidyl functionality produced another potent and selective MAGL inhibitor 156.166,167 
The latter was assessed to almost completely inhibit MAGL at 1 μM concentrations. By either oral or 
intraperitoneal administration in mice, compound 156 manifested an impressive inhibitory capacity 
against MAGL at a low dose of 1 mg/kg in ABPP studies. The inhibition of MAGL induced by 156 was 
observed up to 24 h post-dose. In addition, compound 156 showed no detectable off-target effects at a 10 
μM concentration except ABHD6.166,167 Moreover, it was identified to relieve chronic pain in a model of 
diabetes induced by a combination of high fat diet and streptozotocin in rats (5 mg/kg intraperitoneal 
injection).167 Recently, compound 156 was found to produce anti-allodynia and anti-hyperalgesia through 
the increase of 2-AG levels along with the activation of cannabinoid receptors and mu opioid receptors in 
a CCI model of neuropathic pain (0.43 mg/kg intraperitoneal injection), and to be devoid of 
opioid/cannabinoid-dependent side effects (such as constipation).168 Compounds 155 and 156 can be 
further investigated for their clinical applications. The disclosure of these two potent, selective and 
irreversible MAGL inhibitors could inspire the development of novel selective and irreversible MAGL 
inhibitors. 
Most recently, a novel potent and selective MAGL inhibitor, compound 157 (SAR127303, Figure 
55), was revealed to inactivate MAGL at nanomolar levels (IC50 (mMAGL) = 3.8 nM), markedly elevate 
2-AG levels in mice and produce analgesic effects in several models of inflammation and pain.169 Notably, 
compound 157 displayed high selectivity over most human serine enzymes except ABHD6 and was 
devoid of effects on 170 kinases, ion channels, transporters, and cannabinoid receptors, including CB1 
and CB2. The administration of 157 resulted in a significant increase of 2-AG levels without affecting 
AEA, OEA, and PEA levels at a dose of 8 mg/kg. In addition, compound 157-induced activity was 
detectable until 24 h post-dose.169 Compound 157 elicited anti-nociceptive activities in several models of 
pain and inflammation (such as phenylbenzoquinone (PBQ)-induced writhing, 3 mg/kg oral dose). 
Moreover, compound 157 was identified to attenuate epilepsy symptoms. Interestingly, compound 157-
induced analgesic effects can be reversed by a CB1 (131) but not a CB2 (1) antagonist, which indicated 
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that 157 mainly produced analgesia through a CB1-dependent mechanism.169 Although the administration 
of 157 was demonstrated to be devoid of inducing hypothermia, catalepsy, and hypomotility, it resulted 
in an alteration of learning and memory performance. This adverse property might limit the application 
of 157 in a clinical setting.169 The investigation of its binding mechanism indicated that the Ser132 of 
MAGL could interact with the carbamate moiety of 157 accompanied by the release of 
hexafluoropropyloxy group. The carbonyl oxygen of the carbamate moiety was suggested to serve as an 
H-bond acceptor and bind to Ala61/Met133. The piperidine moiety made contact with one side of Leu251 
through van der Waals interactions. One oxygen atom of the sulfonyl moiety was found to interact with 
the main chain of Asn162 through the formation of H-bond as well as additionally make contact with the 
side chain of Asn162 and the main chain of Leu251 through water-mediated interactions (Figure 57).169 
Like most O-hexafluoropropyloxy carbamates, the hexafluoropropyloxy moiety of 157 served as the 
leaving group during catalysis.169 Furthermore, [11C]-157 has been synthesized as a radiotracer for 
investigating the density and distribution of MAGL, which could be used for the diagnosis of CNS-
dependent disorders (such as nerve injury).170 
6. Other MAGL inhibitors 
Tetrahydrolipstatin (THL, Figure 58), also termed orlistat, is an approved drug to treat obesity 
through the inhibition of lipases.171 In 2003, THL was shown to additionally target DAGLα/β.172 
Furthermore, Di Marzo’s group developed a series of THL derivatives as modulators of 2-AG levels.173 
Notably, the screening of these synthesized THL analogues led to the identification of 158 (OMDM169, 
IC50 = 2.8 µM, Figure 58) as a selective MAGL inhibitor over DAGLα (approximately 7-fold) and FAAH 
(> 7-fold). Compound 158 also exerted poor affinity for CB1 and CB2 receptors.173 Interestingly, 
compound 158 exhibited varied inhibitory potency against MAGL according to the different enzyme 
sources and species.174 In fact, compound 158 produced superior potency in rat brain and rat cerebellum 
rather than in the corresponding mouse tissues.174 Compound 158 was detected to produce anti-
nociception and elevate 2-AG levels without affecting AEA concentrations in mice pre-treated with 
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formalin. However, the elevation of 2-AG levels was only observed in the ipsilateral paw that influenced 
by the administration of formalin, but not in the contralateral paw.174 This result is consistent with the fact 
that 2-AG is produced “on demand”. Like most β-lactone-based enzyme inhibitors, the β-lactone moiety 
of 158 was suggested to covalently and reversibly interact with the Ser122 of MAGL to form an acyl-
enzyme adduct (Figure 59).173 
In 2008, Poupaert and co-workers disclosed a series of arylthioamides derivatives as MAGL 
inhibitors. Although most of these derivatives only inhibited MAGL at millimole levels, logP values made 
arylthioamide a favorable scaffold for the further exploration of MAGL inhibitors.175 Moreover, the 
modification of the amide moiety and the introduction of the sulfur atom appended to the thioamide group 
was performed based on an arylthioamide scaffold.176 Especially, compounds 159 (CK16) and 160 
(CK37) exerted weak activity against MAGL at submicromolar concentrations (IC50 = 0.355 and 0.155 
µM, respectively, Figure 58). Additionally, compound 159 possessed superior selectivity over FAAH (> 
2810 fold) in comparison with 160 (SI = 11).176 This result is consistent with the hypothesis that the Y-
type scaffold favors selectivity of MAGL inhibitors over other serine hydrolases. Interestingly, although 
compounds 159 and 160 manifested similar potencies against MAGL in vitro, compound 159 only slightly 
elevated 2-AG levels while the administration of 160 resulted in a dramatic increase of 2-AG levels in 
vivo. The different effects on the alteration of 2-AG levels could be attributed to the differences in stability 
of 159 and 160.176 Dilution studies indicated that 160 might covalently and irreversibly inactivate 
MAGL.176 
In 2009, two natural terpenoids 161 (pristimerin) and 162 (euphol) (Figure 58) were reported to 
inhibit MAGL at submicromolar concentrations (IC50 = 0.093 and 0.315 µM, respectively).47 Specifically, 
compound 161 rather than 162 was shown to elevate 2-AG levels without alteration of AEA 
concentrations. Moreover, the administration of 161 led to an obvious increase of 2-AG levels in brain 
neurons. Compounds 161 and 162 were hypothesized to reversibly interact with Cys208 and Cys201 of 
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MAGL, respectively. The discovery of 161 and 162 might inspire the exploration of novel reversible 
agents against MAGL.47 
As previously described, numerous 1,3,4-oxadiazol-2-one derivatives were disclosed as dual 
MAGL/FAAH inhibitors. Among these derivatives, compound 163 (Figure 58) exerted optimal potency 
against human recombinant MAGL (IC50 = 0.085 µM), however it also inactivated FAAH with IC50 of 
0.23 µM.114,115 Moreover, another 1,3,4-oxadiazol-2-one derivative 164 (CAY10499, Figure 58) was 
shown to irreversibly and time-dependently inhibit human recombinant MAGL in the nanomolar range 
(IC50 = 0.092 µM).177 Nevertheless, compound 164 was determined to lack selectivity over FAAH (IC50 
= 0.076 µM). Although 164 comprises two possible reactive groups, i.e. carbamate and 1,3,4-oxadiazol-
2-one, the latter functional group is assumed to be responsible for the principal interaction with MAGL.177 
Perspectives 
Following the observation that EC and FAE-mediated biological responses produce analgesia, anti-
inflammation, neuroprotection, gastroprotection, and other protective effects, the elevation of endogenous 
ligand levels through the inhibition of corresponding hydrolases (FAAH, NAAA, and MAGL) has been 
regarded as a potential therapeutic approach for pain, inflammation, depression, anxiety, and 
gastroprotection. Over recent decades, the development of selective FAAH, NAAA, and MAGL 
inhibitors has made many significant strides. Numerous molecules have been shown to inhibit relevant 
endogenous hydrolases at single digit-/sub-nanomolar concentrations and exert attractive analgesic, anti-
inflammatory or tissue-protective efficacy in animal models. Although MAGL inhibitors (such as 151, a 
moderately selective inhibitor) rather than FAAH inhibitors were previously reported to induce CB1-
dependent side effects (hypomotility and hypothermia),178 a highly selective MAGL inhibitor 152 was 
recently identified to be devoid of these adverse effects. Compound 151-induced side effects following 
high-dose treatment might be attributed to its off-target activity against FAAH, consistent with the 
previous finding that dual FAAH/MAGL inhibition resulted in cannabimimetic side effects. In this case, 
highly selective MAGL inhibitors are required for further investigation. 
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Several FAAH inhibitors have been evaluated in clinical trials: compound 58 developed by Johnson 
& Johnson (phase II, treatment for depressive and anxiety disorders), compound 65 synthesized by Pfizer 
(Phase II, treatment for pain, post-traumatic stress disorders and Tourette syndrome, failed to relieve 
osteoarthritic knee induced pain in clinical trials), SSR-411298 (structure not disclosed) developed by 
Sanofi-Aventis (Phase II, treatment for cancer pain and depressive disorders), compound 77 synthesized 
by Merck (phase I, treatment for pain), and V158866 (structure not disclosed) developed by Vernalis 
(Phase II, failed to treat neuropathic pain) (Table 1).179 The lack of analgesia in clinical trials brings a new 
challenge in the development of FAAH inhibitors as antinociceptive agents. Producing analgesia in 
rodents but failing to treat pain in clinical trials may be attributed to the following reasons: (1) the 
discrepancies between animal pain models and human pain disorders. For instance, pain in an animal 
model is usually induced by external stimuli (e.g. pro-inflammatory compound injection, tissue damage), 
whereas human pain in clinical settings is due to complex factors and associated with other disorders (e.g. 
osteoarthritis, colitis, cancer). (2) Emotionality significantly influences pain observation in humans rather 
than in rodents. Anxiety and depression status should be considered in the treatment of patients with pain. 
(3) Biological responses might differ in various species. Is the activation of CB receptors induced by AEA 
elevation after FAAH inhibition equivalent to that induced by exogenous CB receptors agonists in 
humans? Does AEA elevation after FAAH inhibition induce CB-independent effects in humans rather 
than in rodents? Relevant research needs to be carried out in order to answer these issues. Additionally, 
detailed clinical data are often not reported, which also makes reasons for failure unclear. Preclinical pain 
models that are predictive of human pain should be reconsidered if these clinical trial failures are really 
attributed to species differences. In adition to pain, FAAH inhibitors have shown therapeuticpotential in 
inflammation, anxiety and depression in numerous preclinical assays. Of note, clinical trials of FAAH 
inhibitors in other disorders (e.g. depression, anxiety, post-traumatic stress disorders and Tourette 
syndrome) are in progress. Hence, FAAH inhibition can be considered as an interesting target for 
neuroprotection and/or anti-inflammation. 
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Recently, a drug clinical trial tragedy in Bial-Portela company occurred when oral administration of 
an irreversible FAAH inhibitor 165 (BIA 10-2474, Figure 60) induced severe side effects (i.e. one man 
died, five other participants had different degrees of brain injuries), which raises suspicions of FAAH 
inhibitor safety. In late April, a report of the French National Agency for Medicines and Health Products 
Safety (ANSM)179 indicated that this tragedy might be attributed to 165-induced off-target effects in the 
brain. Other pharmaceutical companies, including Johnson & Johnson, Pfizer, Sanofi-Aventis, Vernalis, 
and Merck, have developed several FAAH inhibitors which were administered to a large number of 
patients without observing such severe side effects. After this tragedy, Vernalis disclosed the detailed 
report of a reversible FAAH inhibitor V158866 (IC50 ~60 nM) in clinical trials.180 V158866 was rapidly 
absorbed with a t1/2 of 9.6-18.3 h post a 5-500 mg oral dose. There were no severe or serious adverse 
effects observed post a 5-300 mg daily dose and a 50-500 mg repeated dose. Mild adverse effects (i.e. 
headache, dizziness, somnolence and fatigue) were mainly observed at the highest doses (500 mg 
daily).180 Overall, V158866 was tolerated and did not trigger severe adverse effects even post a high dose 
(500 mg daily). Accordingly, FAAH can be still regarded as a safe target for therapeutic intervention. 
The selectivity and potential off-targets of enzyme inhibitors used for clinical trials should be 
investigated and addressed carefully. In this case, PET ligands could be considered as useful tools for 
distribution and potential off-target studies in humans. To the best of our knowledge, an irreversible 
inhibitor seems to increase potential safety concerns due to its long duration of action.49,111 Therefore, 
development of reversible rather than irreversible inhibitors appears to be more favorable for clinical 
application. Nevertheless, their ability to tightly interact with enzyme makes irreversible inhibitors useful 
tools for the investigation of enzyme function. 
Although there is no MAGL or NAAA inhibitor in clinical trials reported to date, several inhibitors 
of NAAA (such as AM9053 and 130) or MAGL (such as 152, 155, and 156) were disclosed to manifest 
attractive drug-like properties. These compounds could be further investigated for their potential 
preclinical or clinical applications in pain remission, anti-inflammation, and neuroprotection. 
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Additionally, the metabolic stability of β-lactam-based NAAA inhibitors and the selectivity of carbamate-
based MAGL inhibitors are still improvable for the development of potential systemic application.  
As another target in the endocannabinoid system, MAGL inhibitor studies might also be helpful for 
finding the explanation of clinical treatment failure with FAAH inhibitors and investigating potential roles 
of ECs in different disorders (such as inflammation, pain, anxiety and depression). Do AEA and 2-AG 
contribute equally to anti-inflammation, analgesia, anti-anxiety, or anti-depression? If not, how is the 
equilibrium between AEA and 2-AG regulated? More studies are required to answer these questions, since 
some controversy remains. 
Unlike FAAH or MAGL, NAAA inhibitor-induced PEA elevation appears to activate PPAR-α rather 
than cannabinoid receptors, which confers advantageous properties, such as lack of cannabinoid-
dependent adverse effects (e.g. hypomotility and hypothermia). Additionally, PPAR-α activation after 
NAAA inhibition is followed by negative modulation of NF-κB thereby suppressing the pro-inflammatory 
cytokines and COX-2 expression, which makes NAAA an ideal target for anti-inflammation and 
inflammatory pain relief due to the use of COX-2 and pro-inflammatory cytokine (e.g. IL-1β, TNF-α) 
inhibitors as approved anti-inflammatory medicines over several years. 
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109.Minkkila, A.; Saario, S. M.; Käsnänen, H.; Leppänen, J.; Poso, A.; Nevalainen, T. Discovery of 
boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J. Med. Chem. 2008, 51, 
7057-7060. 
110.Liu, P.; Hamill, T. G.; Chioda, M.; Chobanian, H.; Fung, S.; Guo, Y.; Chang, L.; Bakshi, R.; Hong, 
Q.; Dellureficio, J.; Lin, L. S.; Abbadie, C.; Alexander, J.; Jin, H.; Mandala, S.; Shiao, L. L.; Li, W.; 
Sanabria, S.; Williams, D.; Zeng, Z.; Hajdu, R.; Jochnowitz, N.; Rosenbach, M.; Karanam, B.; 
Madeira, M.; Salituro, G.; Powell, J.; Xu, L.; Terebetski, J. L.; Leone, J. F.; Miller, P.; Cook, J.; 
 71
Holahan, M.; Joshi, A.; O'Malley, S.; Purcell, M.; Posavec, D.; Chen, T. B.; Riffel, K.; Williams, M.; 
Hargreaves, R.; Sullivan, K. A.; Nargund, R. P.; DeVita, R. J. Discovery of MK-3168: a PET tracer 
for imaging brain fatty acid amide hydrolase. ACS Med. Chem. Lett. 2013, 4, 509-513. 
111.Chobanian, H. R.; Guo, Y.; Liu, P.; Chioda, M. D.; Fung, S.; Lanza, T. J.; Chang, L.; Bakshi, R. K.; 
Dellureficio, J. P.; Hong, Q.; McLaughlin, M.; Belyk, K. M.; Krska, S. W.; Makarewicz, A. K.; Martel, 
E. J.; Leone, J. F.; Frey, L.; Karanam, B.; Madeira, M.; Alvaro, R.; Shuman, J.; Salituro, G.; Terebetski, 
J. L.; Jochnowitz, N.; Mistry, S.; McGowan, E.; Hajdu, R.; Rosenbach, M.; Abbadie, C.; Alexander, 
J. P.; Shiao, L. L.; Sullivan, K. M.; Nargund, R. P.; Wyvratt, M. J.; Lin, L. S.; DeVita, R. J. Discovery 
of MK-4409, a novel oxazole FAAH inhibitor for the treatment of inflammatory and neuropathic pain. 
ACS Med. Chem. Lett. 2014, 5, 717-721. 
112.Andrzejak, V.; Muccioli, G. G.; Body-Malapel, M.; El Bakali, J.; Djouina, M.; Renault, N.; Chavatte, 
P.; Desreumaux, P.; Lambert, D. M.; Millet, R. New FAAH inhibitors based on 3-carboxamido-5-
aryl-isoxazole scaffold that protect against experimental colitis. Bioorg. Med. Chem. 2011, 19, 3777-
3786. 
113.Tourteau, A.; Leleu-Chavain, N.; Body-Malapel, M.; Andrzejak, V.; Barczyk, A.; Djouina, M.; Rigo, 
B.; Desreumaux, P.; Chavatte, P.; Millet, R. Switching cannabinoid response from CB2 agonists to 
FAAH inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 1322-1326. 
114.Minkkilä, A.; Savinainen, J. R.; Käsnänen, H.; Xhaard, H.; Nevalainen, T.; Laitinen, J. T.; Poso, A.; 
Leppänen, J.; Saario, S. M. Screening of various hormone-sensitive lipase inhibitors as 
endocannabinoid-hydrolyzing enzyme inhibitors. ChemMedChem 2009, 4, 1253-1259. 
115.Käsnänen, H.; Minkkilä, A.; Taupila, S.; Patel, J. Z.; Parkkari, T.; Lahtela-Kakkonen, M.; Saario, S. 
M.; Nevalainen, T.; Poso, A. 1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and 
monoacylglycerol lipase inhibitors: synthesis, in vitro evaluation and insight into potency and 
selectivity determinants by molecular modelling. Eur. J. Pharm. Sci. 2013, 49, 423-433. 
116.Patel, J. Z.; Parkkari, T.; Laitinen, T.; Kaczor, A. A.; Saario, S. M.; Savinainen, J. R.; Navia-Paldanius, 
D.; Cipriano, M.; Leppänen, J.; Koshevoy, I. O.; Poso, A.; Fowler, C. J.; Laitinen, J. T.; Nevalainen, 
 72
T. Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J. Med. Chem. 2013, 56, 8484-
8496. 
117.Wang, X.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S. P.; Kolasa, T.; Surowy, C.; El Kouhen, O. F.; 
Muchmore, S. W.; Brioni, J. D.; Stewart, A. O. Synthesis and evaluation of benzothiazole-based 
analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J. Med. Chem. 2008, 
52, 170-180. 
118.Gustin, D. J.; Ma, Z.; Min, X.; Li, Y.; Hedberg, C.; Guimaraes, C.; Porter, A. C.; Lindstrom, M.; 
Lester-Zeiner, D.; Xu, G.; Carlson, T. J.; Xiao, S.; Meleza, C.; Connors, R.; Wang, Z.; Kayser, F. 
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg. Med. 
Chem. Lett. 2011, 21, 2492-2496. 
119.Min, X.; Thibault, S. T.; Porter, A. C.; Gustin, D. J.; Carlson, T. J.; Xu, H.; Lindstrom, M.; Xu, G.; 
Uyeda, C.; Ma, Z.; Li, Y.; Kayser, F.; Walker, N. P.; Wang, Z. Discovery and molecular basis of 
potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc. Natl. Acad. Sci. U. S. A. 
2011, 108, 7379-7384. 
120.Gowlugari, S.; DeFalco, J.; Nguyen, M. T.; Kaub, C.; Chi, C.; Duncton, M. A.; Emerling, D. E.; Kelly, 
M. G.; Kincaid, J.; Vincent, F. Discovery of potent, non-carbonyl inhibitors of fatty acid amide 
hydrolase (FAAH). MedChemComm 2012, 3, 1258-1263. 
121.Sundermann, T.; Fabian, J.; Hanekamp, W.; Lehr, M. 1-Heteroaryl-3-phenoxypropan-2-ones as 
inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: effect of the replacement 
of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability. 
Bioorg. Med. Chem. 2015, 23, 2579-2592. 
122.Pearson, J. P.; Bernier, S.; Jackson, C.; Wakefield, J. D.; Sykes, K. A.; Liong, E.; Carey, G.; Busby, 
R. W.; Currie, M. G.; Lichtman, A. H.; Milne, G. T.; Profy, A. T. Oral treatment with the selecctive 
FAAH inhibitor MM-433593 relieves thermal hyperalgesia induced by E.coli lipopolysaccharide in 
C57BLACK6/J mice via cannabinoid CB1 receptor. 22nd Annual Symposium of the International 
Cannabinoid Research Society: Freiburg, 2012. 
 73
123.Banijamali, A. R.; Wakefield, J. D.; Mermerian, A. H.; Busby, R. W. Metabolism and disposition of 
MM-433593, a selective FAAH-1 inhibitor, in monkeys. Pharmacol. Res. Perspect. [Online] 2014, 
2, e00059. 
124.Keith, J. M.; Hawryluk, N.; Apodaca, R. L.; Chambers, A.; Pierce, J. M.; Seierstad, M.; Palmer, J. A.; 
Webb, M.; Karbarz, M. J.; Scott, B. P.; Wilson, S. J.; Luo, L.; Wennerholm, M. L.; Chang, L.; Rizzolio, 
M.; Chaplan, S. R.; Breitenbucher, J. G. 1-Aryl-2-((6-aryl) pyrimidin-4-yl) amino) ethanols as 
competitive inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 2014, 24, 1280-1284. 
125.Tsuboi, K.; Hilligsmann, C.; Vandevoorde, S.; Lambert, D.; Ueda, N. N-
cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-
acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem. 
J. 2004, 379, 99-106. 
126.Yamano, Y.; Tsuboi, K.; Hozaki, Y.; Takahashi, K.; Jin, X.-H.; Ueda, N.; Wada, A. Lipophilic amines 
as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase. Bioorg. Med. Chem. 2012, 20, 
3658-3665. 
127.Saturnino, C.; Petrosino, S.; Ligresti, A.; Palladino, C.; De Martino, G.; Bisogno, T.; Di Marzo, V. 
Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing 
acid amidase. Bioorg. Med. Chem. Lett. 2010, 20, 1210-1213. 
128.Petrosino, S.; Iuvone, T.; Di Marzo, V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic 
opportunities. Biochimie 2010, 92, 724-727. 
129.Li, Y.; Yang, L.; Chen, L.; Zhu, C.; Huang, R.; Zheng, X.; Qiu, Y.; Fu, J. Design and synthesis of 
potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory 
compounds. PLoS One [Online] 2012, 7, e43023. 
130.West, J. M.; Zvonok, N.; Whitten, K. M.; Vadivel, S. K.; Bowman, A. L.; Makriyannis, A. 
Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing 
acid amidase inhibition. PLoS One [Online] 2012, 7, e43877. 
131.Solorzano, C.; Antonietti, F.; Duranti, A.; Tontini, A.; Rivara, S.; Lodola, A.; Vacondio, F.; Tarzia, G.; 
 74
Piomelli, D.; Mor, M. Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl) amides 
as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J. Med. Chem. 2010, 53, 5770-5781. 
132.Armirotti, A.; Romeo, E.; Ponzano, S.; Mengatto, L.; Dionisi, M.; Karacsonyi, C.; Bertozzi, F.; Garau, 
G.; Tarozzo, G.; Reggiani, A.; Bandiera, T.; Tarzia, G.; Mor, M.; Piomelli, D. β-Lactones inhibit N-
acylethanolamine acid amidase by S-acylation of the catalytic N-terminal cysteine. ACS Med. Chem. 
Lett. 2012, 3, 422-426. 
133.Duranti, A.; Tontini, A.; Antonietti, F.; Vacondio, F.; Fioni, A.; Silva, C.; Lodola, A.; Rivara, S.; 
Solorzano, C.; Piomelli, D.; Tarzia, G.; Mor, M. N-(2-Oxo-3-oxetanyl) carbamic acid esters as N-
acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property 
relationships. J. Med. Chem. 2012, 55, 4824-4836. 
134.Ponzano, S.; Bertozzi, F.; Mengatto, L.; Dionisi, M.; Armirotti, A.; Romeo, E.; Berteotti, A.; Fiorelli, 
C.; Tarozzo, G.; Reggiani, A.; Duranti, A.; Tarzia, G.; Mor, M.; Cavalli, A.; Piomelli, D.; Bandiera, T. 
Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid 
esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. J. Med. Chem. 2013, 
56, 6917-6934. 
135.Sasso, O.; Moreno-Sanz, G.; Martucci, C.; Realini, N.; Dionisi, M.; Mengatto, L.; Duranti, A.; 
Tarozzo, G.; Tarzia, G.; Mor, M.; Bertorelli, R.; Reggiani, A.; Piomelli, D. Antinociceptive effects of 
the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. PAIN® 2013, 154, 
350-360. 
136.Vitale, R.; Ottonello, G.; Petracca, R.; Bertozzi, S. M.; Ponzano, S.; Armirotti, A.; Berteotti, A.; 
Dionisi, M.; Cavalli, A.; Piomelli, D.; Bandiera, T.; Bertozzi, F. Synthesis, structure-activity, and 
structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylethanolamine acid 
amidase (NAAA) inhibitors. ChemMedChem 2014, 9, 323-336. 
137.Ponzano, S.; Berteotti, A.; Petracca, R.; Vitale, R.; Mengatto, L.; Bandiera, T.; Cavalli, A.; Piomelli, 
D.; Bertozzi, F.; Bottegoni, G. Synthesis, Biological evaluation, and 3D QSAR study of 2-methyl-4-
oxo-3-oxetanylcarbamic acid esters as N-acylethanolamine acid amidase (NAAA) inhibitors. J. Med. 
 75
Chem. 2014, 57, 10101-10111. 
138.Fiasella, A.; Nuzzi, A.; Summa, M.; Armirotti, A.; Tarozzo, G.; Tarzia, G.; Mor, M.; Bertozzi, F.; 
Bandiera, T.; Piomelli, D. 3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase 
(NAAA) inhibitors suitable for systemic administration. ChemMedChem 2014, 9, 1602-1614. 
139.Ribeiro, A.; Pontis, S.; Mengatto, L.; Armirotti, A.; Chiurchiù, V.; Capurro, V.; Fiasella, A.; Nuzzi, 
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